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Background: Although muscarinic antagonists are currently used to treat asthma, there remain 
various characteristics that have yet to be fully elucidated. The other major class of 
bronchodilators, b2-agonists, have been extensively studied and through these investigations, 
it was found that significant tolerance to the bronchoprotective effects of b2-agonists occurs 
along with increased allergen responsiveness. These findings have informed clinical use of b2-
agonists to ensure patient safety. For this reason, formulations of long-acting b2-agonists are 
combined with inhaled corticosteroids and a recommended upper limit for dosing short-acting 
b2-agonists use has been established. By contrast, the regular use effects of muscarinic 
antagonists on methacholine and allergen responsiveness are not well established. These 
characteristics can be determined through methacholine challenge testing and allergen 
inhalation challenges, respectively.  
Methods: Two double blind, placebo-controlled, randomized crossover clinical trials were 
performed. The first trial examined the regular use effect of the inhaled short-acting 
muscarinic antagonist (SAMA), ipratropium bromide (Atrovent®), on methacholine-
responsiveness in twelve well-controlled mild asthmatics. This investigation employed 
methacholine challenge testing at various timepoints to determine if tolerance developed 
following 40µg of ipratropium thrice daily for 1-week. The second trial examined the regular 
use effect of the inhaled long-acting muscarinic antagonist (LAMA), tiotropium bromide 
(Spiriva® Respimat®), on the allergen-induced early asthmatic response in thirteen well-
controlled mild allergic asthmatics. This investigation used an allergen-inhalation challenge 
and the indirect measures of inflammation: fractional exhaled nitric oxide (FeNO) and sputum 
differential cell counts (sDCC). Tiotropium was administered 5µg once daily for 1-week. 
Results: The first trial found that tolerance to the bronchoprotective effect of ipratropium did 
not occur after 1-week of regular use. The second trial found that regular tiotropium slightly 
increased the early asthmatic response to allergen and did not inhibit eosinophil recruitment 
after allergen.  
Conclusion: The absence of tolerance to ipratropium bromide suggest muscarinic antagonists 
may be safer alternatives for regular use compared to b2-agonists. This finding is contradicted 
by the observed increase in allergen responsiveness following regular use of tiotropium. 
Muscarinic antagonists need to be further evaluated to determine their safety and efficacy as 
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1.0 INTRODUCTION AND LITERATURE REVIEW 
1.1 Asthma 
1.1.1 Overview  
Asthma is a respiratory disease characterized by airway hyperresponsiveness (AHR) to 
various stimuli, reversible airflow obstruction, chronic airway inflammation, and tissue 
remodelling. Asthma affects 2.5 million Canadians and up to 18% of populations worldwide 
(Global Initiative for Asthma, 2021; Statistics Canada, 2019). Common asthma triggers include 
allergen, exercise, smoke, and cold air which act in the airway to induce narrowing, causing 
airflow obstruction (O' Byrne et al., 2009). Diagnosis commonly occurs following a clinical 
history of wheezing, cough, chest tightness and/or dyspnoea accompanied by a favourable 
response to asthma management therapies (Coates et al., 2017; O' Byrne et al., 2009) and may be 
confirmed by demonstration of variable airflow obstruction or AHR to inhaled stimuli that act 
directly on airway smooth muscle (e.g. methacholine). However, the heterogenous nature of 
asthma complicates treatment, management, and diagnosis. Attempts have been made to 
categorize clinically similar asthmatic patient groups into asthma phenotypes (Miles, 2012). 
These phenotypes include allergic, non-allergic, adult-onset, persistent airflow limitation and 
asthma with obesity (Global Initiative for Asthma, 2021). However, these clinical patterns do not 
always appear to be directly linked to pathologic features and specific treatment response. 
Instead, focus should be on the underlying disease mechanisms contributing to an individual’s 
asthma in order to provide targeted therapy. Progress has been made in endotyping asthma into 
subgroups based on pathophysiological disease mechanisms to allow for specific targeted 
therapies (Côté et al., 2020). This thesis will focus on the general population of mild asthmatics 
and the sub-population of allergic asthmatics. 
1.1.2 General Pathophysiology  
Airway inflammation was identified to be central to asthma pathogenesis, which shifted 
asthma therapies to an anti-inflammatory focus (O' Byrne et al., 2009). However, the type of 
inflammation present can vary (Hargreave & Nair, 2009). The sputum and bronchial wall of 
asthmatics contains inflammatory granulocytes involved in the underlying airway inflammation, 
such as eosinophils and neutrophils. Sputum cell samples may be used to identify inflammatory 
subtypes in asthmatics and are most often comprised of macrophages, lymphocytes, and 
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contaminating squamous epithelial cells in addition to the inflammatory granulocytes (Figure 
1.1). Eosinophilic inflammation (Figure 1.1 Panel A) tends to occur with an overexpression of T 
helper type 2 (Th2) lymphocytes and type 2 innate lymphoid cells (ILC-2) (Khalaf et al., 2019). 
This inflammatory subtype is associated with allergic asthma, although many non-allergic 
asthmatics also have eosinophilic inflammation. Non-eosinophilic or neutrophilic (Figure 1.1 
Panel B) asthma may be driven by T helper type 17 (Th-17) lymphocytes. Less common are 
mixed neutrophilic/eosinophilic inflammation and paucigranulocytic asthma where few 
inflammatory cells are present (Papi et al., 2018). Different chemical mediators are released by 
inflammatory cells and can cause tissue damage leading to airway remodelling, heightened 
airway responsiveness and chronic airflow limitation (Hargreave & Nair, 2009).  
Figure 1.1 Examples of sputum cell samples for eosinophilic inflammation (Panel A) and 
neutrophilic inflammation (Panel B). Both samples contain macrophages (red), lymphocytes 
(orange), eosinophils (purple), neutrophils (blue) and contaminating squamous epithelial 
cells (green). Although both samples contain all cells, the proportion of eosinophils is much 
greater in A and that of neutrophils is much greater in B. 
AHR can occur from hypercontractile airway smooth muscle in response to various stimuli 
(Papi et al., 2018). Certain triggers may initiate worsening of airway inflammation and asthma 
exacerbations, including allergens and viruses (Mims, 2015). When an asthma exacerbation 
occurs, airway swelling, secretions and smooth muscle constriction contribute to airway 
obstruction. Variability in obstruction is defined by both improvement and/or deterioration in 
symptoms and lung function over time (Global Initiative for Asthma, 2021). Progression to 
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incompletely reversible airflow obstruction signals that structural changes may have occurred, 
collectively referred to as remodelling (Hargreave & Nair, 2009).  
Airway remodelling includes epithelial damage, cilial dysfunction, goblet cell hyperplasia, 
mucous gland metaplasia and increased airway smooth muscle mass (Papi et al., 2018). 
Pathological changes to the airway mucosa may lead to increased mucous production and 
increased mucous in the airway lumen (Mims, 2015). 
No single cause of asthma has been identified. However, it has been long understood that 
there is a genetic component (Miles, 2012). Several polymorphisms exist in genes for airway 
epithelial barrier function and immune response which may be contributing factors to asthma 
pathogenesis (Papi et al., 2018). Environmental factors including pollution, allergen, infection 
and social stress are also considered as potential causes (Apter, 2010). It is likely that an array of 
genetic and environmental factors influence asthma development.  
1.1.3 Allergic Asthma 
Pollens, animal antigens and house dust mite were linked to airway disease in the late 19th 
century and allergens are now recognized as the most important cause of asthma (Cockcroft, 
2014). The majority of asthmatics are allergic and atopic children are at an increased risk of 
developing asthma (Gauvreau et al., 2015). Clinically, allergic asthma includes sensitization to 
environmental allergens and a correlation between allergen exposure and symptom development 
(Schatz & Rosenwasser, 2014). While allergic asthma can arise at any age, onset in childhood is 
more likely to occur. The spectrum of allergic asthma can range from mild to severe. Seasonal 
sensitivities may lead to individual variations in allergic asthma severity based on the presence of 
environmental allergens. Hence the term, hay fever, which describes allergic symptoms 
coinciding with haying season (Gauvreau et al., 2015).  
Atopic (or allergic) asthma is considered a type 2 inflammatory disease mediated by T-helper 
CD4+ lymphocytes and type 2 inflammatory cytokines: interleukin-4 (IL-4), IL-5, IL-9 and IL-
13 (Burks et al., 2020). In allergic asthmatics, inhaled allergen induces airway responses via 
cellular inflammatory cascades that lead to bronchoconstriction. At mucosal barriers including 
the airway epithelium, an array of immune cells survey the environment in order to provide 
innate and adaptive immunity as needed (Bosmans et al., 2017). Dendritic cells (DC) are 
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antigen-presenting cells responsible for processing and presenting antigen to prime naïve T 
lymphocytes. DC take up antigen via receptor-mediated endocytosis in the case of the major cat 
antigen Fel d 1, constitutive micropinocytosis for some pollens or phagocytosis for particulate 
allergens. Any antigens taken up by DC accumulate in the endocytic compartment where they 
are cleaved into immunogenic peptides and loaded on major histocompatibility complex (MHC) 
class II molecules. The T cell receptor (TCR) on CD4+ T lymphocytes recognizes antigens in the 
context of the MHC class II molecules. Through this interaction (Fig. 1.2), DC stimulate naïve T 
lymphocytes to mature into Th2 cells that produce a variety of type 2 inflammatory cytokines 
leading to immunoglobulin E (IgE) production, eosinophil recruitment, mast cell development, 
goblet cell hyperplasia and AHR (Gauvreau et al., 2015). The binding of allergen-specific IgE to 
FceRI receptors on the surface of mast cells and basophils initiates allergen-induced airway 
responses (Fig. 1.3). Cross-linkage of IgE by allergen causes mast cell degranulation of 
preformed mediators including histamine and the activation of eicosanoid pathways to produce 
prostaglandins (PG) like PGD2 and cysteinyl leukotrienes (CysLTs) including LTC4, LTD4 and 
LTE4. 
Figure 1.2 Th2 cellular responses to allergen leading to recruitment of inflammatory cells. 










Figure 1.3 IgE-mediated release of bronchoconstricting mediators during early asthmatic 
responses to allergen.  
Histamine and CysLTs are responsible for allergen-induced bronchoconstriction, which can 
occur as an early asthmatic response (EAR), late asthmatic response (LAR) or both, known as a 
dual response. The EAR develops shortly after allergen exposure and is maximal after 10- to 20-
minutes (Boulet et al., 2007; Cockcroft, 2014; Marciniuk et al., 2021). However, the LAR is a 
recurrence of bronchoconstriction that can manifest between 3 to 8-hours after allergen 
inhalation. Approximately 60% of adults with allergic asthma are dual responders who 
experience both the EAR and LAR (Gauvreau et al., 2015). However, this may be an 
overestimate as only 35% of historical Asthma Research Lab allergic asthmatic participants were 
dual responders in Saskatchewan (Marciniuk et al., 2021). While cellular mechanisms behind the 
late response are not fully established, histamine and CysLTs appear to be involved (Davis et al., 
2009). Late sequelae including increased AHR to direct acting stimuli and inflammation may 
occur in addition to the LAR (Cockcroft, 2014). AHR is a defining feature of asthma and 
increased AHR to histamine and methacholine up to 10-fold and lasting 7-10 days has been 
documented following allergen inhalation in the laboratory (Boulet et al., 2007; Cockcroft, 
2014). This finding is correlated to real world allergen exposure as individuals developing a 
LAR and AHR to ragweed pollen in the lab are more likely to demonstrate seasonal AHR during 
ragweed pollen season (Boulet et al., 1983; Cockcroft, 2014). Allergen-induced airway 
inflammation associated with the LAR is defined by an increase in airway inflammatory cells, 
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demonstrated by bronchoscopy, bronchoalveolar lavage and induced sputum differential cell 
counts (Gauvreau et al., 2015). Marked airway eosinophilia occurs in dual and isolated late 
responders (Cockcroft, 2014). Airway basophils and less consistently, airway neutrophils can 
also increase following allergen but to a lesser extent than eosinophils (Gauvreau et al., 2015). 
Initiation of allergen-induced airway inflammation occurs when crosslinking of allergen-
specific IgE on mast cells (Fig. 1.3) induces the release of inflammatory cytokines, IL-3, IL-4, 
IL-5, and IL-6 (Gauvreau et al., 2015). Proinflammatory cytokines induce inflammation through 
various mechanisms summarized in Table 1.1. In addition, release of CysLTs from mast cells 
contributes to inflammation by promoting eosinophil survival (Lee et al., 2000), indirect 
chemotaxis by stimulating the production of chemoattractants (Peters-Golden et al., 2006) and 
direct chemotaxis by LTE4 (Gauvreau et al., 2001). Isolated early responders, compared to dual 
responders, show smaller increases in airway inflammatory cells despite a similar magnitude of 
acute bronchoconstriction following allergen inhalation. Therefore, mast cell degranulation 
cannot be the only mechanism responsible for airway inflammation. The allergen-induced 
inflammatory response could also occur with the activation and maturation of DC in response to 
the epithelial cytokine, thymic stromal lymphopoietin (TSLP) (Levine & Wenzel, 2010). DC are 
the most potent antigen-presenting cell in the lung, playing a major role in immune responses 
(Gauvreau et al., 2015). This is confirmed in mouse models of allergic asthma that demonstrate 
allergen induced Th2 sensitization of DC and subsequent eosinophilic airway inflammation. 
Regardless of phenotype, most asthmatics are predisposed towards type 2 airway 
inflammation based on the presence of airway alarmins including TSLP, IL-25 and IL-33 
(Gauvreau, Sehmi, et al., 2020; Schatz & Rosenwasser, 2014). TSLP is released by airway 
epithelium in response to aggravating environmental factors, including allergen (Gauvreau, 
Sehmi, et al., 2020). Certain inflammatory disorders including asthma and atopic dermatitis show 
dysregulated production of TSLP and elevated TSLP expression in asthma is correlated with the 
degree of airway obstruction and disease severity. ILC2 are responsive to these alarmins and 
secrete high amounts of type 2 cytokines (Gauvreau, Sehmi, et al., 2020; Scanlon & Mckenzie, 
2012). The role of ILC2 in the lung has not been fully elucidated; however, their potential to 
drive type 2 responses suggests ILC2 are involved in driving type 2 inflammation. This is 
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illustrated by elevated ILC2 in severe asthma and persistent eosinophilia when compared to mild 
asthma (Gauvreau, Sehmi, et al., 2020). 
Table 1.1 Cytokines involved in allergic airway responses. 
Abbreviations: IgE: immunoglobulin E; iNOS: inducible nitric oxide synthase; AHR: airway 
hyperresponsiveness; Th2: T-helper type2.  
Of particular interest is the role of TSLP in driving dendritic cell-mediated T lymphocyte 
differentiation. TSLP can induce the production of Th2-attracting chemokines including thymus 
and activation-regulated chemokine (TARC/CCL17) and macrophage-derived chemokine 
(MDC/CCL22) (Ito et al., 2005). In addition, TSLP increases dendritic cell expression of 
costimulatory molecules: CD40, CD80, CD86, CD83, HLA-DR and OX40L (Guo et al., 2010; 
Ito et al., 2005). The OX40-OX40L interaction between DC (OX40L) and T lymphocytes 
(OX40) plays an important role in triggering Th2 cell immune responses in both human and 
murine models. Furthermore, when CD4+ T lymphocytes are activated by TSLP-primed DC, the 
 
Cytokine Function 
IL-3 Mast cell growth factor; prolongs eosinophil survival (Burks et al., 2020; Marshall et 
al., 1989). 
IL-4 Increases IgE production due to B cell class switching; causes differentiation and 
proliferation of T lymphocytes; indirectly increases iNOS expression; increases 
epithelial permeability (Gauvreau et al., 2015; Levine & Wenzel, 2010; Wenzel et al., 
2007). 
IL-5 Eosinophilopoietin: differentiation, maturation, and survival of eosinophils (Burks et 
al., 2020). 
IL-6 Immunoglobulin secretion factor (Marshall et al., 1989). 
IL-9 Mast cell development and stimulates production of mast cell cytokines and 
chemokines (Burks et al., 2020). 
IL-13 Induces goblet cell hyperplasia leading to mucus overproduction; enhances non-
specific AHR; indirectly increases iNOS expression; increases epithelial permeability 
(Gauvreau et al., 2015; Levine & Wenzel, 2010; Wenzel et al., 2007). 
TSLP Alarmin: Central regulator of Th2 immune responses (Gauvreau, Sehmi, et al., 
2020). 
IL-25 Alarmin: Drives Th2 immune deviation through action on lymphocytes and ILC2 
(Burks et al., 2020). 
IL-33 Alarmin: Acts as a transcription factor to enhance the Th2 inflammatory response 
and a chemoattractant for Th2 cells (Burks et al., 2020). 
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T lymphocytes are stimulated to produce large amounts of type 2 cytokines. Therefore, TSLP 
polarizes DC towards a Th2-promoting profile with major implications in allergic asthma (Gori 
et al., 2017).  
1.1.4 Asthma Management 
A range of pharmacological treatments targeting various aspects of asthma 
pathophysiology are available and generally fall into one of two categories: rescue or 
controller. Rescue treatments relieve acute bronchoconstriction and include bronchodilators 
such as b2-agonists (e.g. salbutamol). Controller treatments tend to target airway inflammation 
and include inhaled corticosteroids (e.g. budesonide). Treatment regimens are divided into 
tracks or steps based on asthma severity (Global Initiative for Asthma, 2021). However, 
asthma severity is classified by the intensity of treatment required to maintain disease control 
(Yang et al., 2021). This complicates initial treatment as severity can only be determined 
retrospectively after treatment has been initiated. While very mild/mild asthma severity 
implies low risk of morbidity and mortality, asthma exacerbations can cause death in mild 
asthmatics. For this reason, it is extremely important that disease control is maintained with 
asthma treatments. The 2021 Canadian Thoracic Society (CTS) guidelines suggest very mild 
asthma is treated with short-acting b2-agonist (SABA) as needed no more than twice a week. 
Previous recommendations suggested mild asthma could also be controlled with SABA as 
needed and occasional low dose inhaled corticosteroids (ICS) during mild episodes of poor 
control. However, given the risk of severe exacerbations, it is now suggested that mild 
asthmatics receive daily low dose ICS to maintain control over inflammation and SABA as 
needed to relieve episodes of acute bronchoconstriction. Alternatively, mild allergic 
asthmatics may be treated with daily leukotriene receptor antagonist (LTRA) instead of ICS 
and mild asthmatics may use combination therapy of ICS/long acting-b2-agonist (LABA) as 
needed for symptoms. Asthma is considered well-controlled when daytime symptoms occur £ 
2 days/week, mild nighttime symptoms occur < 1 night/week and SABA reliever is required £ 
2 doses weekly.  
Treatment of severe and uncontrolled or difficult-to-control asthma may require different 
approaches and has been the subject of many clinical investigations (Côté et al., 2020). While 
the use of oral corticosteroids (OCS) is usually effective, monoclonal antibodies (e.g. anti-
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IgE, anti-IL-5) and long-acting muscarinic antagonist add on therapy (e.g. tiotropium 
bromide) have also proved beneficial in this population and may be preferred to avoid OCS 
side effects. Given the indication and use of tiotropium bromide in severe asthma, it becomes 
particularly important to further understand the role of muscarinic signalling and blockade in 
asthma. 
1.2 Airway Muscarinic Signalling 
Muscarinic antagonists have been used for respiratory problems dating back centuries to 
Ayurvedic healers in India (Schlueter, 1986; Williams & Rubin, 2018). In 1802, asthma 
cigarettes were formulated with muscarinic antagonists and marketed for the treatment of asthma 
(Herxheimer, 1959). Muscarinic antagonists exert their action by inhibiting muscarinic receptors 
of the airways to induce bronchodilation. Airway cholinergic signalling may have a role in the 
pathogenesis of asthma and thus cholinergic modulation may be an effective management 
mechanism.  
1.2.1 Neuronal Cholinergic Signalling 
The bronchoconstrictor role of acetylcholine via parasympathetic nervous system signalling 
has been well established (Kistemaker et al., 2012). Acetylcholine (ACh) is released from the 
vagal parasympathetic preganglionic fibers onto peri-bronchial ganglia to stimulate subsequent 
ACh release from the post-ganglionic fibers onto airway smooth muscle and submucosal glands 
(Novelli et al., 2012). Cholinergic innervation occurs throughout the airways but is greatest in 
the larger airways (White, 1995). Post-ganglionic neuronal signalling uses muscarinic ACh 
receptors (mAChR) that are G-protein coupled and exist in 5 subtypes, M1-M5 (Nizri & Brenner, 
2013). Muscarinic receptors mediate neuronal cholinergic effects on the airways via the M1, M2 
and M3 subtypes. The excitatory M1 and M3 receptors promote ACh release through G-protein 
coupling to Gq/G11 and subsequent activation of phospholipase C and phosphatidylinositol 
turnover to increase intracellular calcium (Williams & Rubin, 2018). M1 receptors facilitate 
neural transmission on the parasympathetic ganglia, while M3 receptors mediate cholinergic 
action on the smooth muscle, vascular endothelium, and submucosal glands of the airways 
(Novelli et al., 2012). Neuronal cholinergic signalling results in bronchoconstriction of airway 
smooth muscle and mucus secretion. Modulatory M2 receptors mediate inhibitory effects on ACh 
release through Gi/G0 coupling that inhibits adenylate cyclase and induces hyperpolarization of 
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the cell membrane (Williams & Rubin, 2018). The presence of M2 receptors on the post-ganglion 
endings of vagal cholinergic fibers inhibits presynaptic ACh release in response to increased 
synaptic concentrations of ACh (Novelli et al., 2012; Williams & Rubin, 2018). Acetylcholine 
esterase (AChE) is highly effective at degrading neuronal ACh to prevent it from diffusing as a 
signal molecule (Wessler & Kirkpatrick, 2008). 
Pathogenic neuronal cholinergic signalling in asthma has been characterized as AHR to 
inhaled cholinergic agonists (e.g. methacholine) and in some cases, enhanced cholinergic tone 
and mucus hypersecretion (Novelli et al., 2012). However, increasing evidence has implicated 
additional cholinergic signaling from non-neuronal cells in immune system modulation. 
1.2.2 Non-Neuronal Cholinergic Signalling  
Cholinergic receptors and signal transduction pathways can be used by non-neuronal cells as a 
mode of communication (Wessler & Kirkpatrick, 2008). The airway non-neuronal cholinergic 
system consists of mast cells, leukocytes, macrophages, DC, and airway epithelial cells. Much of 
the research on the non-neuronal cholinergic signalling employed by immune cells stems from in 
vitro murine models and ex vivo human tissue data. Given the relevance of these data to human 
allergic asthma, cholinergic signalling among lymphocytes, DC, mast cells, airway epithelium 
and eosinophils will be focussed on.  
Release of ACh from non-neuronal cells mediates paracrine and autocrine regulatory 
functions that are not fully elucidated to date (Wessler & Kirkpatrick, 2008). Cells with the 
ability to produce and release ACh have been identified by immunohistochemistry demonstrating 
the presence of choline acetyltransferase (ChAT), the main ACh synthesis enzyme (Wessler & 
Kirkpatrick, 2001). While various immune cells may produce ACh, the ability of T lymphocytes 
and DC to synthesize and release ACh becomes particularly important in the polarization of DC 
and T lymphocytes to a Th2 profile. Upon stimulation with antigen, T lymphocytes are triggered 
to express ChAT and M5 receptors (Kawashima, 2004). Resting DC also do not express ChAT; 
however, expression can be induced by endotoxin stimulation (Kawashima et al., 2007). 
Therefore, it is theorized that cholinergic signalling may be activated during antigen presentation 
and the ACh released by DC and T lymphocytes acts on their own mAChR and nicotinic ACh 
receptors (nAChR) to modulate functions.  
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Expression of mAChRs and nAChRs differs among phenotypic cell functions (Wessler & 
Kirkpatrick, 2008). The a7 nAChR seems to mediate anti-inflammatory effects while mAChR 
provide a proinflammatory signal (Gori et al., 2019). DC are key players of innate type 2 
immunity that influence subsequent development of adaptive immune responses (Bosmans et al., 
2017). DC express cholinergic receptors and evidence suggests that cholinergic signals modulate 
the activity of these cells. Murine DC can express the a7 nAChR subtype and all five mAChR 
subtypes. An ex vivo human dendritic cell investigation showed stimulation of DC with ACh via 
mAChR increased the expression of OX40L and increased the production of chemokines: 
MDC/CCL2 and TARC/CCL17 (Gori et al., 2017). Lymphocyte proliferation and production of 
IL-4, IL-5 and IL-13 also increases with ACh-primed DC, suggesting that ACh polarizes DC 
towards a Th2 promoting profile in a similar mechanism to TSLP. In fact, ACh and TSLP 
synergistically increase OX40L, CD83 and HLA-DR when incubated together. This enhancing 
effect could be due to upregulated expression of the M3 receptor by TSLP. These cholinergic 
effects are mediated by the M3 receptor on murine DC (Gori et al., 2019). Therefore, M3 is 
considered the main receptor involved in ACh-activation of DC.  
Given the role of mast cells in airway responses to allergen, cholinergic signalling 
mechanisms influencing mast cell function are of potential importance in allergic asthma. Both 
mAChR and nAChR have been identified on mast cells (Bosmans et al., 2017). Mast cells reside 
in the airway mucosa and can become activated by inhaled allergens causing degranulation of 
histamine and CysLTs. However, M1 stimulation by ACh inhibits the release of histamine from 
mast cells in ex vivo human bronchi (Reinheimer et al., 2000). In addition, the physiological 
pathway for mast cell activation via IgE crosslinking at the FceR is effectively inhibited by ACh 
(Reinheimer et al., 1997). M1 receptor blockade on mast cells would remove this cholinergic 
inhibition and therefore, may enhance histamine release in response to allergen. This is not 
conserved in murine models and thus murine data on non-neuronal cholinergic signalling should 
be interpreted with caution (Reinheimer et al., 2000). In fact, murine models demonstrate the 
opposite effect with increased mast cell sensitivity to ACh in the presence of IgE, causing 
cholinergic histamine release (Masini et al., 1985). Since histamine is partially responsible for 
allergen-induced bronchoconstriction, therapies should aim to reduce histamine release. For 
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example, antihistamines are effective at mast cell stabilization and protection against allergen-
induced asthmatic responses (Davis et al., 2009).  
Eosinophils are considered central effector cells in allergic inflammation (Bosmans et al., 
2017). Accumulation of eosinophils in the bronchial wall is regulated by several mechanisms 
including the release of chemoattractant factors that signal egression from the bloodstream to this 
secondary site (Håkansson et al., 1990; Koyama et al., 1998). In bovine bronchial epithelial cell 
models, ACh stimulates the release of eosinophil chemotactic factors (Koyama et al., 1998) and 
therefore, cholinergic signalling at structural airway epithelium may enhance eosinophil 
infiltration. It is suggested that bronchial epithelium is involved in initiating inflammatory 
responses, perhaps doing so with an efficient autocrine cholinergic signalling pathway (Gosens 
et al., 2006; Proskocil et al., 2004). In addition to mediating chemotaxis, cholinergic signalling 
may alter eosinophil function as eosinophils express M1 receptors under certain conditions, such 
as chronic obstructive pulmonary disease (COPD). However, the effect of ACh on eosinophils is 
unknown (Profita et al., 2005). 
Finally, the role of immune cell crosstalk with nerves is an important area of interest. A 
bidirectional relationship exists between the nervous system and immune system and likely 
involves cholinergic signalling (Bosmans et al., 2017). Neurons express cytokine receptors and 
cytokines may provide simultaneous modulation of immune and neuronal function (Chavan et 
al., 2017). Both allergen inhalation and airway inflammation can phenotypically change vagal 
afferent nerves leading to bronchospasm by previously inert stimuli (Mazzone & Undem, 2016). 
While these neuro-immune interactions are highly complex, they likely contribute to asthma 
pathophysiology. For example, eosinophil-nerve interactions are demonstrated to occur under 
inflammatory conditions in the lung (Bosmans et al., 2017). During inflammatory states, 
eosinophils may localize to airway nerves by recognizing neuronal adhesion molecules and 
undergo subsequent activation (Kingham et al., 2003). Activated eosinophils release major basic 
protein (MBP), an antagonist at M2 receptors that can cause a loss of M2 function. An impaired 
autoregulatory role of M2 in decreasing ACh release can cause increases in vagally induced 
bronchoconstriction and mucous production. Thus, eosinophils may be recruited by non-neuronal 
cholinergic signalling and subsequently impair neuronal cholinergic signalling mechanisms.  
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1.2.3 Short-Acting Muscarinic Antagonist: Ipratropium Bromide 
Ipratropium bromide (Atrovent®), previously called SCH 1000, was the subject of over 1,000 
clinical articles in the first 15-years of its release (Schlueter, 1986). It is a short-acting 
muscarinic antagonist (SAMA) administered therapeutically via the pressurized metered-dose 
inhaler (pMDI) and the first modern inhaled muscarinic antagonist for relieving 
bronchoconstriction (Davis et al., 2018; Williams & Rubin, 2018). Modern muscarinic 
antagonists are synthetic derivatives of alkaloid compounds that are modified to have little 
systemic absorption and blood-brain barrier translocation (Williams & Rubin, 2018). For this 
reason, inhaled muscarinic antagonists exhibit very few systemic side effects at therapeutic doses 
and have negligible effects on the heart (Schlueter, 1986). Inhibition of salivary secretions and 
dry mouth may occur at doses higher than clinical recommendations (Cugell, 1986). Inhaled 
muscarinic antagonists bind both to the active site and to an allosteric site, changing the active 
site conformation (Williams & Rubin, 2018). Ipratropium has non-selective affinity for 
muscarinic receptors of the airways including M1, M2 and M3 subtypes. While M1 and M3 
receptor blockade induces bronchodilation, M2 blockade increases release of ACh from vagal 
endings, counteracting the bronchodilator effect to some extent (Sposato et al., 2005). Therefore, 
the non-selective nature of ipratropium bromide may limit its use as a bronchodilator.  
Bronchodilation mediated by muscarinic antagonists occurs primarily in larger airways, 
compared to b2-agonist bronchodilators which act on both small and large airways (Ingram et al., 
1977). A standard dose of ipratropium is 40µg as needed and each actuation of the pMDI 
delivers 20µg (Davis et al., 2018). The criteria for a significant post-bronchodilator response are 
generally accepted to be an increase in the forced expiratory volume in 1-second (FEV1) by 12-
15% and 200mL (Pellegrino et al., 2005). Changes in FEV1 < 8% or < 150mL are within 
measurement variability. The bronchodilation response to ipratropium has been well documented 
(Cockcroft et al., 1982; Petanjek et al., 2007; Ruffin et al., 1977). Ipratropium demonstrates a 
mean increase in FEV1 by 19.14% in mild to moderate allergic asthmatics (Petanjek et al., 2007). 
This was replicated in the general asthmatic population with a mean increase in FEV1 > 20% 
(Cockcroft et al., 1982). This relationship is reported to be dose-dependent with 80µg of 
ipratropium inducing double the bronchodilation (36.3% versus 17.0% mean increase in FEV1) 
of a 40µg dose (Lulling et al., 1981). Bronchodilation onsets within 15-minutes but has been 
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reported to begin as quickly as 30-seconds and lasts 4 to 6-hours (Pakes et al., 1980). The 
maximal effect is reached after 1.5-hours. Fast onset of bronchodilation is an important property 
of SABA and SAMA required to treat acute bronchoconstriction (Papiris et al., 2009). Therefore, 
the bronchodilator action of ipratropium has been frequently compared to the SABA, salbutamol 
(Ventolin®). Salbutamol induces bronchodilation rapidly and is the first-line rescue treatment for 
acute symptomatic bronchospasm (Williams & Rubin, 2018). Salbutamol tends to exhibit greater 
bronchodilator efficacy compared to that of ipratropium in asthmatics (Novelli et al., 2012). 
However,  b2-agonists are known to produce cardiovascular side effects and tremor that some 
patients may not tolerate (Ruffin et al., 1978; Schlueter, 1986). In that case, ipratropium may be 
used instead given its low side effect profile. While regular use of ipratropium is expected to 
elicit tolerance to the bronchodilator effect (Friedman et al., 1983; Emmelin, 1961), clinical 
investigations have failed to demonstrate this (Cockcroft et al., 1982; Newcomb et al., 1985). 
Tolerance to bronchodilation is difficult to demonstrate as there is an upper limit to maximal 
airway dilation and with current asthma control guidelines, it is difficult to find asthmatic 
participants with significant resting bronchoconstriction. Instead, bronchoprotection can serve as 
a method of measuring tolerance development as it is not limited by a maximal response or by 
the absence of resting bronchoconstriction.  
Bronchoprotection occurs when a drug antagonizes, either by specific antagonism or 
functional antagonism, stimulus-induced bronchoconstriction. Methacholine is a cholinergic 
agonist that induces bronchoconstriction by direct stimulation of M3 receptors on airway smooth 
muscle (Sposato et al., 2005). Muscarinic antagonists elicit bronchoprotection against 
methacholine by competitive antagonism. b2-agonists exhibit bronchoprotection by functional 
antagonism, protecting against constriction by inducing bronchodilation. Methacholine challenge 
testing is used to quantitate pharmacological bronchoprotection by calculating the shift in the 
dose of methacholine required to elicit a 20% fall in FEV1 (methacholine PD20). Comparing 
methacholine PD20 when untreated to the PD20 following drug administration quantifies 
bronchoprotection (Westbury et al., 2018). The shift in methacholine PD20 required to overcome 
the bronchoprotection by a drug is expressed as a doubling dose shift. A 40µg dose of 
ipratropium produces bronchoprotection in a 2.8 doubling dose shift (Sposato et al., 2005). This 
is a dose-response effect as 80µg of ipratropium provides a 5.8 doubling dose shift in 
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methacholine PD20 (Bandouvakis et al., 1981). Bronchoprotection lasts at least 6-hours and is 
absent by 12-hours following administration of 40µg of ipratropium (Illamperuma et al., 2009). 
In comparison, single dose (200µg) salbutamol induces, on average, bronchoprotection by about 
2.7 doubling doses (Cockcroft et al., 2020).  
Regular use of b2-agonists quickly leads to the development of tolerance to the 
bronchoprotective effect against methacholine-induced constriction (Bhagat et al., 1995; Kalra et 
al., 1996; Stewart et al., 2012). Administering 200µg of salbutamol twice daily produces a loss 
of bronchoprotection after only five doses and is significant following the seventh dose (Stewart 
et al., 2012). ICS do not prevent tolerance development, suggesting airway inflammation does 
not play a role (Kalra et al., 1996). In addition, regular use of salbutamol has also been shown to 
increase airway responses (acute bronchoconstriction at lower doses and increased airway 
inflammation) to allergen (Cockcroft et al., 1993). While the loss of bronchoprotection against 
methacholine occurs at low doses (200µg salbutamol daily for 1-week), loss of 
bronchoprotection against allergen (i.e. increased allergen responsiveness) was only documented 
to occur after 800µg daily for 1-week, suggesting different mechanisms are responsible (Bhagat 
et al., 1996). Tolerance to bronchoprotection against methacholine may be due to altered b2-
receptor physiology after repeated b2-agonist exposure (Bhagat et al., 1995) which could include 
uncoupling of b2-receptors from the cell membrane, internalization of the receptor (Cooper & 
Panettieri, 2008) and/or decreased receptor mRNA stability (Hadcock et al., 1989).  
Muscarinic receptor upregulation occurs in ex vivo human tissues from the brain and gut 
following repeated exposure to a muscarinic antagonist (Friedman et al., 1983; Newcomb et al., 
1985). Extrapolating this effect to the lung suggests that regular use of muscarinic antagonist 
bronchodilators may lead to tolerance as a result of M3 receptor upregulation. One previous 
study found no change in the bronchoprotective effect of ipratropium against methacholine 
following 60µg of ipratropium four times daily for 3-weeks (Newcomb et al., 1985). However, 
rebound hyperresponsiveness to methacholine 24-hours after discontinuation of ipratropium was 
documented. Various aspects of this study differ from current tolerance investigations and 
tolerance to the bronchoprotective effect of ipratropium should be re-evaluated. 
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With emerging evidence on the role of cholinergic signalling in allergic asthma, muscarinic 
antagonist efficacy in allergic asthma is of great interest. Historically, pre-treatment with 
muscarinic antagonists including atropine and ipratropium prior to an allergen inhalation 
challenge produced rather equivocal data. Atropine is a naturally occurring anticholinergic 
alkaloid and was likely the first pharmacologic agent used for asthma in the western world 
(Restrepo, 2007). A major finding of these early investigations was that the cholinergic pathway 
did not appear to be involved to a large extent in the airway obstruction induced by allergen 
inhalation in allergic asthmatics. Inhalation of 1.2mg/mL of atropine in solution with allergen 
produced asthmatic responses quantitatively similar to the inhalation of allergen alone (Fish et 
al., 1977). However, 1.5-2.5 mg of atropine administered intravenously reduced airway 
resistance following allergen inhalation in five of seven participants (Yu et al., 1972). Various 
administration routes of atropine have been tested including inhalation, sublingual preparations, 
and intravascular (IV) injections (Itkin & Anand, 1970). Local inhaled atropine is more effective 
at blocking cholinergic signalling than systemic IV administration although near toxic doses are 
required to have anticholinergic effects in the lung when given via the IV route. Systemic 
atropine use is associated with high rates of classical anti-cholinergic adverse effects and inhaled 
atropine has poor water solubility when compared to modern synthetic muscarinic antagonists 
like ipratropium (Novelli et al., 2012). For this reason, atropine is, for the most part, no longer 
used in the treatment of bronchospasm (Cugell, 1986).  
Data on single-dose ipratropium efficacy against allergen-induced responses generally shows 
protection against the EAR in a portion of study populations, suggesting there may be innate 
differences in allergic asthmatics that may predispose them to better protection with a muscarinic 
antagonist. An 80µg dose of ipratropium (via MDI) protected against allergen induced 
bronchoconstriction, with seven of twelve participants experiencing ³ 25% reduction in the 
decrease in FEV1 following allergen (Cockcroft et al., 1978). The reduction in FEV1 decrease 
was significant for the study group. In four participants who developed a LAR, ipratropium 
produced no inhibition. Perhaps due to insufficient protection by ipratropium during the LAR 
development given its short-half life (Table 1.2). Ipratropium also significantly reduced the 
response to histamine inhalation. This finding was confirmed by another investigation where a 
40µg dose of ipratropium (via MDI) provided protection against allergen and histamine, 
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measured by tracking the number of breaths required to produce a fall in FEV1 of 20% (Clarke et 
al., 1982). The asthmatic response to grass pollen was fully inhibited in six of ten participants 
following a single 1mg dose of ipratropium (via MDI) despite increased doses of pollen 
administered (Orehek et al., 1975). These data are contradicted by the finding that 1mg of 
nebulized ipratropium had no significant effect on the allergen-induced fall in FEV1 in a group of 
six allergic asthmatics (Howarth et al., 1985). However, there was a slightly lower mean 
maximal fall in FEV1 following ipratropium versus placebo treatment of 20.6% and 25.5%, 
respectively. Collectively these results suggest that ipratropium has some protective effect 
against allergen-induced responses in a portion of allergic asthmatics.  
1.2.4 Long-Acting Muscarinic Antagonist: Tiotropium Bromide 
Tiotropium bromide monohydrate (Spiriva® Respimat®) is currently the only long-acting 
muscarinic antagonist (LAMA) approved for use by Health Canada and recommended by the 
CTS as add-on therapy in asthma (Fitzgerald et al., 2017). The Respimat® inhaler device 
delivers a mist containing 2.5µg of tiotropium per actuation (Spiriva® Respimat® Product 
Monograph, 2017). Recommended dosing is 2 actuations (5µg) once daily at the same time each 
day. Tiotropium is kinetically selective for the M3 receptor but binds to M1, M2 and M3 receptors 
of the airways (Kistemaker & Gosens, 2015). The dissociation half-life of tiotropium is greatest 
on the M3 receptor (Table 1.2), creating a duration of action over 24-hours (Sposato et al., 2008). 
In asthma, its effective half-life is 34-hours (Spiriva® Respimat® Product Monograph, 2017). 
Given this long duration of action, its use is cautioned in patients with narrow-angle glaucoma 
and urinary retention.  
Table 1.2 Anticholinergic selectivity on muscarinic receptors.  
Adapted from Kistemaker et al [2015].  
Muscarinic 
antagonist 
Binding Affinity (-log M) Half-life (hr) 
M1 M2 M3 M1 M2 M3 
Ipratropium 9.40 9.53 9.58 0.1 0.03 0.22 
Tiotropium 10.80 10.69 11.02 10.5 2.6 27 
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The indication for tiotropium as an add-on therapy is in severe asthmatics who still experience 
symptoms while on ICS/LABA combination therapy and have experienced one or more severe 
asthma exacerbations in the last year (Spiriva® Respimat® Product Monograph, 2017). Clinical 
trials under this indication demonstrated significant lung function improvements in FEV1 when 
tiotropium is added-on, compared to ICS/LABA alone. Tiotropium also significantly reduced the 
risk of exacerbations, including severe exacerbations. The benefits of tiotropium treatment arise 
after several doses. It is currently not recommended to use tiotropium as a monotherapy in 
asthma based on a lack of data showing any efficacy. As a monotherapy, a single dose of 10µg 
of tiotropium provides mild bronchodilation between 5.5-11% from baseline that lasts 24-hours 
in mild asthmatics (O’Connor et al., 1996). Another investigation found 5µg tiotropium provided 
no bronchodilation 1-hour after inhalation (Blais et al., 2016). However, a borderline statistically 
significant increase in FEV1 by 94mL was present 24-hours after inhalation. These study 
populations were comprised of mild well-controlled asthmatics who have relatively low airway 
constriction at rest which may contribute to the low level of bronchodilation achieved.  
A single dose (5µg) of tiotropium provides bronchoprotection against methacholine-induced 
constriction on a magnitude of about 4-doubling doses from baseline which remain statistically, 
but not clinically significant after 7-days (Blais et al., 2016). Currently there are no data on 
tiotropium protection against allergen-induced asthmatic responses. However, animal data show 
promise in tiotropium efficacy against allergen-induced changes. Ovalbumin (OVA)-sensitized 
and challenged guinea pigs and murine are commonly used for studying inhaled allergen-induced 
changes in the airways (Smith & Broadley, 2007). In BALB/C mice challenged with OVA, 
tiotropium prevented the acute inflammatory reaction following allergen challenge and decreased 
eosinophils in bronchoalveolar lavage fluid (Ohta et al., 2010). Tiotropium also prevented the 
production of type 2 cytokines including IL-4, IL-5 and IL-13 following allergen exposure. In 
both rats and mice, tiotropium inhibited the OVA-induced LAR (Raemdonck et al., 2012). This 
was replicated in OVA-challenged guinea pigs where tiotropium significantly inhibited the LAR, 
but not inflammatory cell infiltration in bronchoalveolar lavage fluid. However, another study 
with OVA-challenged guinea pigs found tiotropium partially prevented eosinophilia in the 
airways and effectively inhibited allergen-induced airway remodelling (Bos et al., 2007). 
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Collectively, these preclinical data suggest that tiotropium should be investigated clinically in 
allergic asthma. 
 The protective mechanism of tiotropium against allergen-induced changes may be blockade 
of the M3 receptor that is involved in ACh-polarization of DC to a Th2 profile. An ex vivo 
murine dendritic cell investigation demonstrated that tiotropium is efficacious in preventing 
ACh-induced increases in inflammatory cytokines (Gori et al., 2019). However, knockout of the 
M3 receptor does not change eosinophil or type 2 cytokine levels in OVA-challenged mice 
(John-Schuster et al., 2017). Inhibiting the polarization of DC towards a Th2 profile in humans 
by targeting TSLP with therapeutic antibodies has had significant efficacy in protecting against 
allergen-induced responses (Gauvreau, Hohlfeld, et al., 2020; Gauvreau et al., 2014). An injected 
anti-TSLP monoclonal antibody partially attenuated both the EAR and LAR, decreased blood 
and sputum eosinophil counts and decreased fractional exhaled nitric oxide levels (Gauvreau et 
al., 2014). Recently an anti-TSLP antibody fragment was developed as a dry-powder inhaler and 
demonstrated similar attenuation of allergen-induced changes (Gauvreau, Hohlfeld, et al., 2020). 
Perhaps the remaining allergen responsiveness in the TSLP-investigations is due to an intact 
cholinergic signalling pathway promoting Th2 polarization that could be blocked by muscarinic 
antagonism. Therefore, the effect of tiotropium on allergic responses should be evaluated, 
despite conflicting preclinical data. The role of the M1 receptor in inhibiting histamine release 
from mast cells could be partially responsible for the mixed effects observed in preclinical 
investigations as tiotropium binds to, and has a significant half-life on the M1 receptor (Table 
1.2). By contrast, b2-agonists inhibit mast cell degranulation and show efficacy against inhibiting 
allergen-induced asthmatic responses in humans (Eiser, 1991; Howarth et al., 1985; Ruffin et al., 
1978). However, regular use of b2-agonists enhances both the EAR and LAR, suggesting airway 
inflammation may occur with regular b2-agonist use from mast cell dysfunction (Cockcroft et al., 
2007; Cockcroft et al., 1993; Cockcroft et al., 1995). In conclusion, the cholinergic role in 
asthma is complex and requires further investigation.  
1.3 Introduction Summary 
Asthma is a heterogenous disorder, complicating treatment, and management. Further 
understanding of the complex disease mechanisms underlying various asthma endotypes means 
that therapies can specifically target underlying pathophysiology. The mechanisms behind 
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allergic asthma have yet to be fully determined, especially the role of cholinergic non-neuronal 
signalling in human immune responses. Cholinergic signalling mechanisms can be targeted by 
inhaled muscarinic antagonists, which are available and prescribed for use in asthma based on 
their bronchodilator effect on airway smooth muscle. However, various properties of muscarinic 
antagonists have yet to be characterized. For example, little is known on regular use of 
muscarinic antagonists and whether tolerance develops to their bronchoprotective effect. In 
addition, the efficacy of LAMA against allergen-induced asthmatic responses has yet to be 
determined. By contrast, our understanding of the detrimental effects following regular b2-
agonists has improved our knowledge of allergic responses and helped inform clinical use of 
these therapies.  
1.4 Rationale  
Bronchodilators including salbutamol and ipratropium protect against inhaled 
bronchoconstrictor stimuli, such as methacholine. Dose-dependent bronchoprotection against 
methacholine induced bronchoconstriction has been documented for both ipratropium and 
salbutamol (Bandouvakis et al., 1981; O'Connor et al., 1992; Sposato et al., 2005). Regular use 
of b2-agonists results in tolerance to the bronchoprotective effect (Bhagat et al., 1995; O'Connor 
et al., 1992). Only one study conducted more than 35 years ago reported the absence of tolerance 
and the presence of rebound hyperresponsiveness following regular use of ipratropium bromide 
(Newcomb et al., 1985). This finding should be confirmed or refuted by investigating the effect 
of daily administration, and subsequent withdrawal, of ipratropium bromide on methacholine 
responsiveness in asthma. 
Recent studies have suggested a non-neuronal cholinergic signalling role in allergic asthma 
through immune cell modulation. ACh has a modulatory action on muscarinic receptors of DC to 
promote and induce an allergic or type 2 response (Gori et al., 2019; Gori et al., 2017). It is 
theorized that muscarinic antagonists could protect the airways by inhibiting the ACh-induced 
polarization of dendritic cells towards the Th2-profile in addition to inhibiting constriction (Gori 
et al., 2017). Ovalbumin challenge data from animal models treated with tiotropium show 
reductions in measures of allergen induced changes including eosinophil recruitment and type 2 
cytokine production (Bos et al., 2007; Ohta et al., 2010). There are recent reports of synergism 
between ACh and TSLP in promoting the Th2 phenotype in ex vivo dendritic cell investigations 
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(Gori et al., 2019; Gori et al., 2017). This synergistic effect can be inhibited by muscarinic 
receptor antagonism of murine DC. Data documenting anti-TSLP efficacy in the human allergen 
challenge model shows a significant but not complete reduction in allergen-induced changes 
(Gauvreau et al., 2014). The residual responses could be due to cholinergic signalling via the 
muscarinic receptors of immune cells. Collectively, these data suggest that the effects of 
tiotropium on allergen induced airways responses should be evaluated clinically in humans.  
Evaluating the safety of regular use of muscarinic antagonists and their efficacy in allergic 





This chapter will provide background regarding the purpose and function of each method. The 
method sub-chapters detail specifics from the clinical studies in Chapters 3 and 4 for performing 
spirometry, methacholine challenge testing, skin prick testing, allergen inhalation challenges, 
fractional exhaled nitric oxide measurements, sputum induction and sputum differential cell 
counts. 
2.1 Spirometry 
Spirometry measures the maximal amount of air an individual can exhale (and inhale) with 
maximal effort (Graham et al., 2019) and it is useful for diagnosing and monitoring lung disease. 
Spirometric maneuvers produce volume and flow data as a function of time. Lung function can 
be predicted based on age, weight, height, sex, and ethnicity as these factors are often 
determinants of lung size. A maneuver consists of 4 phases: maximal inspiration to total lung 
capacity (TLC), a blast of expiration, continued expiration up to 15-seconds, and inspiration back 
to TLC. Spirometry can generate the FEV1 and the forced vital capacity (FVC) which are 
reproducible measures of lung function, provided maximal effort and proper technique are 
performed.  
Variable airway obstruction is a characteristic of asthma that can be demonstrated by 
spirometry. Obstruction manifests as a reduced ratio in FEV1 to FVC and/or decreased FEV1 
when compared to predicted values (Global Initiative for Asthma, 2021). When performed before 
and after administration of a rapid-acting bronchodilator, spirometry can confirm the presence of 
reversible airway obstruction (Brigham & West, 2015; Global Initiative for Asthma, 2021). 
While the CTS and Global Initiative for Asthma (GINA) do not list specific criterion for asthma 
severity, the National Heart, Lung and Blood Institute (NHLBI) defines mild asthma to include 
an FEV1 > 80% of the predicted value (Yang et al., 2021). 
Bronchoprovocation testing utilizes spirometry to monitor induced bronchoconstriction by 
measuring FEV1 data. During bronchoprovocation testing, shortened spirometry maneuvers 
consist of a maximal inspiration to TLC followed by a blast expiration for at least 2-seconds 
(Coates et al., 2017). Shortened maneuvers reduce fatigue while still producing FEV1 data, the 
outcome required to demonstrate a fall in lung function. The quality of bronchoprovocation tests 
relies on the participant’s ability to perform reproducible spirometric maneuvers.  
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2.1.1 Method 
During each study visit, spirometry was used to establish a baseline FEV1 using an nSpire 
KoKo® spirometer (Carestream Medical Ltd, Oakville, Ontario, Canada). Baseline lung function 
was evaluated based on FEV1 and forced vital capacity (FVC) data using standardized equations 
(Quanjer et al., 2012). 
2.2 Bronchoprovocation Testing 
AHR is a key characteristic of asthma and transient airway responses can be induced by direct 
and indirect acting stimuli (Pawankar et al., 2009). Direct agonists, including methacholine and 
histamine, elicit airway narrowing through direct interaction with receptors on airway smooth 
muscle cells. Indirect stimuli such as exercise, adenosine monophosphate, mannitol and allergen, 
act to elicit airway narrowing via indirect pathways resulting in the release of endogenous 
bronchoconstricting stimuli from surrounding cells (e.g. histamine from mast cells) as well as 
pro-inflammatory cytokines (Coates et al., 2017). Bronchoprovocation testing with direct (e.g. 
methacholine) and indirect-acting stimuli (e.g. allergen) is an invaluable tool used in clinical 
asthma research. Early investigations with histamine in the 1940s demonstrated 
bronchoconstriction occurring at lower doses and to a greater extent in asthmatics, leading to the 
development of AHR testing with direct stimuli as diagnostic measures (Davis & Cockcroft, 
2012). Normal airways do not usually respond significantly to direct acting stimuli within the 
dose range required to induce bronchoconstriction in hyperresponsive asthmatic airways. Asthma 
pharmacotherapies often undergo investigations with methacholine challenge testing to 
effectively measure drug efficacy, duration, tolerance, and safety. For more than three decades, 
allergen bronchoprovocation testing has been employed to mimic various acute and chronic 
features of allergic asthma in the laboratory and provides a tool to evaluate asthma therapies 
(Diamant et al., 2013).  
2.2.1 Methacholine Challenge Testing 
Methacholine (MCh) is a synthetic structural analog of the neurotransmitter acetylcholine that 
can directly stimulate M3 muscarinic receptors on airway smooth muscle, inducing 
bronchoconstriction in hyperresponsive airways (Coates et al., 2017). While AHR to 
methacholine is a cardinal feature of asthma, it has been documented in other airway disorders 
including COPD, cystic fibrosis, and allergic rhinitis (Davis & Cockcroft, 2012). AHR to direct 
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stimuli (e.g. methacholine) is quantified by the provocative dose (MCh PD20) or concentration 
(MCh PC20) causing a 20% fall in baseline FEV1 (Coates et al., 2017; Cockcroft et al., 1983; 
Davis et al., 2017). AHR to methacholine is characterized by increased sensitivity or lower PD20, 
and increased reactivity (Davis et al., 2018). Methacholine Challenge Testing (MCT) can be used 
in research and clinically as a diagnostic agent to confirm the presence of AHR to methacholine 
that is suggestive of asthma (Davis & Cockcroft, 2012). If MCh PD20 > 400µg, the MCT is 
considered negative (Coates et al., 2017). The negative predictive power of the MCT can rule out 
clinically current AHR to methacholine with reasonable certainty. Taken together, a negative 
MCh PD20, normal lung function parameters (e.g. FEV1,) and the absence of bronchodilator 
response can refute an asthma diagnosis. Within a stable mild asthmatic individual, MCT is 
highly reproducible and MCh PD20 tends to vary less than 1 doubling dose (Inman et al., 1998). 
Therefore, a difference in MCh PD20 ³ 1 doubling dose is assumed to be clinically significant 
(Inman & Norman, 2006) and suggests improved (i.e. increased MCh PD20) or worsened (i.e. 
decreased MCh PD20) control. However, false negative challenges (MCh PD20 > 400µg) can 
occur in atopic asthmatics outside of allergy season (Davis & Cockcroft, 2012). In addition to 
assessing the level of AHR in an individual, MCT are also used to evaluate the 
bronchoprotective effect of pharmacotherapies. Bronchoprotection occurs when a drug 
antagonizes methacholine-induced bronchoconstriction. Anticholinergic therapies such as 
ipratropium, are competitive M3 receptor antagonists which block methacholine binding, thereby 
preventing bronchoconstriction (Crimi et al., 1992; Davis et al., 2018). However, increasing the 
dose of methacholine will overcome the inhibitory effect, induce bronchoconstriction, and shift 
the dose response curve to the left (Blais, Davis, et al., 2017). 
2.2.1.1 Method 
Methacholine challenges were performed in the current studies (Chapters 3 and 4) according 
to the volumetric method (Davis et al., 2017). Following baseline spirometry, participants 
inhaled 0.5mL of aerosolized normal saline (diluent) by tidal breathing, using the Aerogen 
Solo® vibrating mesh nebulizer (Canadian Hospital Specialties Ltd, Oakville, Ontario, Canada) 
until the entire volume had been delivered (~ 2-minutes). At 30- and 90-seconds post-inhalation, 
a shortened spirometry maneuver was performed to obtain FEV1. Administration of the diluent 
controlled for any reactivity to the inhalation of a mist prior to inhalation of the constricting 
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agent, methacholine. A fall in FEV1 >10% from baseline following diluent indicates sensitivity 
to the inhalation of a mist and the MCT would be continued with caution. The lowest of 30- and 
90-second post-diluent FEV1 values was used to establish a target fall in FEV1 of at least 20%.  
Provocholine (Methapharm, Inc., Brantford, Ontario, Canada) reconstituted with normal 
saline was prepared in doubling dilutions from 2.5µg up to 1600µg (Chapter 3) or 400µg 
(Chapter 4) for methacholine inhalation. Five-minutes after beginning diluent inhalation, the first 
0.5mL dose of methacholine was aerosolized to completion, followed again by FEV1 maneuvers 
at 30-seconds and 90-seconds. Subsequent doses were administered in a doubling fashion at 5-
minute intervals until a fall in FEV1 ³ 17% had been achieved or the maximum dose of 
methacholine had been administered. The maximum dose of methacholine that could be 
administered varied according to the study protocol and study visit requirements. MCh PD20 
values were calculated using interpolated (formula 2.1) or extrapolation (formula 2.2), 
respectively. 
Formula 2.1 fall in FEV1 at final dose > 20% (Cockcroft et al., 1983; Davis et al., 2017): 




D1 = second to last dose of MCh administered 
D2 = last dose of MCh administered causing a fall in FEV1 ³ 20% 
R1 = the fall in FEV1 after D1 
R2 = the fall in FEV1 after D2 
 Formula 2.2 fall in FEV1 at final dose ³ 17% and < 20% (Jokic et al., 1998): 
 Extrapolated MCh PD20 = [ !"#$%&	%	)$##	*+	,-.!		]	𝑥	𝑙𝑎𝑠𝑡	𝑑𝑜𝑠𝑒	𝑜𝑓	𝑚𝑒𝑡ℎ𝑎𝑐ℎ𝑜𝑙𝑖𝑛𝑒	𝑎𝑑𝑚𝑖𝑛𝑖𝑠𝑡𝑒𝑟𝑒𝑑 
The magnitude of bronchoprotection (i.e. the dose shift) provided by asthma therapies (e.g. 
bronchodilators) was quantified using Formula 2.3 (O'Connor et al., 1992): 





MCT can help predict response to allergen as early airway responses are dependent on the 
degree of AHR to non-allergic stimuli (e.g. methacholine or histamine) and levels of allergen-
specific circulating IgE (Boulet et al., 2007; Cockcroft et al., 2019). The prediction equation 
(Formula 2.4) was developed using the relationship between the provocative concentration of 
allergen causing a 20% fall in FEV1 (allergen PC20) and histamine PC20 data (Cockcroft et al., 
1987). Historically, histamine PC20 has been interchangeable with MCh PC20 for investigations 
using the Wright® nebulizer to deliver MCh (Cockcroft et al., 2005). This equation can be 
effectively used to predict allergen responsiveness with the Solo® nebulizer by modifying for 
differences between the nebulizers and using Solo® MCh PD20 data (converted to equivalent 
PC20 data) in the prediction equation (Cockcroft et al., 2019). It has been established that a 
Wright® MCh PC20 of 16mg/mL equates to a Solo® PD20 of 400µg (Blais et al., 2018; Davis et 
al., 2017). Therefore, a MCh PD20 generated with the Solo® nebulizer can be converted into an 
equivalent PC20 to be used in the allergen prediction equation by using the relationship in 
Formula 2.4 (Davis et al., 2017): 
Converted MCh PC20 = /01	2'!#+3  
After sufficient allergen bronchoprovocation testing data with the Solo® nebulizer are 
obtained, a prediction equation specific to this nebulizer could be developed.  
2.2.2 Allergen Inhalation Challenge 
Allergen-induced mast cell degranulation of mediators including histamine and CysLTs are 
responsible for acute bronchoconstriction captured as the fall in FEV1 during the early asthmatic 
response (EAR) (Davis et al., 2005; Gauvreau et al., 2015). Histamine and CysLTs also induce 
bronchoconstriction during the late asthmatic response (LAR) (Davis et al., 2009). The EAR is 
defined as the maximum fall in FEV1 that manifests between 0 to 3-hours following allergen 
inhalation while the LAR is the maximum fall in FEV1 beginning 3- to 8-hours after allergen 
(Blais, Cockcroft, et al., 2017). The EAR may also be quantified as the provocative dose (EAR 
PD20) or concentration (EAR PC20) of allergen required to elicit a 20% fall in FEV1.  
Allergen inhalation challenges (AIC) are useful to look at efficacy of drugs against the 
allergen-induced asthmatic responses (Inman et al., 1995). When the dose of allergen 
administered is kept constant within an individual, both the EAR and LAR are reproducible. 
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Thus, the allergen challenge can be used as a tool when evaluating asthma medications to detect 
changes in allergen-induced asthmatic responses.  
The EAR is dependent on both non-allergic airway responsiveness and the level of allergen 
specific IgE (Cockcroft et al., 2019). Therefore, MCT, Skin Prick Test (SPT) and Skin Test 
Endpoint (STE) titration can be used to predict the EAR PC20. Skin tests diagnose allergy by 
demonstrating IgE mediated allergic sensitivities (Pawankar et al., 2009). There is a high degree 
of correlation between reported allergic asthma symptoms, skin prick tests and provocative 
challenges; therefore, skin tests are a first-line diagnostic method prior to allergen inhalation 
challenges.  
In a SPT, both positive and negative controls are used to control for inter-patient variability in 
cutaneous reactivity (Pawankar et al., 2009). The negative control is important in dermographic 
patients who display wheal and erythema in response to a prick alone. The negative control can 
also detect differences in pricking device such as a lancet or syringe as well as variations in tester 
technique. Variability between tester technique can be controlled for by ensuring that the same 
individual performs all skin prick tests within a study (Blais et al., 2019). A reaction at the 
negative control site can impair the interpretation of allergen reaction sites (Pawankar et al., 
2009). The positive control site serves as a comparison for the relative sensitivity of allergen 
sites and can detect rare patients who are poorly reactive to histamine or have accidentally taken 
an antihistamine medication.  
2.2.2.1 Method 
In the tiotropium study (Chapter 4), the allergen for the allergen inhalation challenge was 
selected from available study allergens based on the largest wheal response from the SPT and a 
clinically relevant history of inducing allergic asthma. Available allergens were obtained from 
Omega Laboratories, Montreal QC or Hollister Stier, Spokane, Washington and included 
standardized extracts of cat hair, timothy grass, and house dust mite dermatophagoides 
pteronyssinus (HDM-DP) as well as a negative control and histamine (positive control). Wheal 
measurements were taken at their peak reaction time between 10-15-minutes by two 
perpendicular measurements of the wheal in millimetres.  
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Table 2.1 Stock concentrations for standardized allergen extracts. 
 
Abbreviations: HDM-DP: house-dust mite DP. 
Allergens were initially diluted to 1:8 and subsequent 2-fold dilutions were performed to 
create the range of concentrations from 1:8 to 1:32,000. The STE was determined as previously 
described (Blais et al., 2019) using duplicate skin tests with the mean wheal size measured at 10-
minutes. The weakest concentration of the selected allergen that induced a 2-mm wheal or less 
was established as the STE. Once the wheal response was recorded, topical corticosteroid cream 
and/or an ice pack was provided as necessary.  
In combination with the MCh PC20, the STE was used to predict the EAR PC20 using 
Formula 2.5 (Cockcroft et al., 1987): 
Predicted EAR PC20 = 0.68	𝑥 𝑙𝑜𝑔(𝑀𝐶ℎ	𝑃𝐶+,	𝑥	𝑆𝑇𝐸	𝐷𝑖𝑙𝑢𝑡𝑖𝑜𝑛) 
To account for the differences in the predicted EAR PC20 in terms of the Wright® nebulizer 
and the EAR PD20 with the Solo® nebulizer, the starting dilution for the allergen challenge was 
set at 6-doubling dilutions below the predicted EAR PC20. Prior to the allergen challenge, 
spirometry was measured in triplicate with the highest FEV1 value providing the baseline to 
which a 20% fall in FEV1 post-allergen inhalation would be determined (Cockcroft et al., 2019). 
Doubling 0.5mL doses of allergen were inhaled to completion by tidal breathing at 12-minute 
intervals using the Solo® nebulizer. Duplicate (one-minute apart) FEV1 measurements were 
performed 10-minutes after allergen inhalation. If the FEV1 fell 16-19.9%, a spirometry 
maneuver was repeated after an additional 10-minutes and if lung function improved, another 
dose of allergen was administered. If after 10-minutes the FEV1 further declined or stayed the 
same, no further doses were given. The response was followed at timed intervals up until 5-hours 
post-inhalation. After collecting data on inflammatory measures, a 200µg dose of salbutamol 
was inhaled to reverse any lasting bronchoconstriction. To prevent the development of a late 
response, a single 500µg dose of fluticasone propionate was inhaled. Participants were allowed 
to leave the laboratory when the FEV1 was at least 90% of baseline.  





 The delivered dose of allergen was calculated by Formula 2.6 (Cockcroft et al., 2019) 
using allergen concentrations from Table 2.1: 
Delivered Dose of Allergen =𝐴𝑙𝑙𝑒𝑟𝑔𝑒𝑛	(!"#$%
&'
)	𝑥	𝑁𝑒𝑏𝑢𝑙𝑖𝑧𝑒𝑟	𝑣𝑜𝑙𝑢𝑚𝑒	𝑥	𝑅𝑒𝑠𝑝𝑖𝑟𝑎𝑡𝑜𝑟𝑦	𝑑𝑢𝑡𝑦	𝑐𝑦𝑐𝑙𝑒 
 Solo® Nebulizer volume = 0.5mL 
 Respiratory duty cycle = 0.4 (Blais et al., 2020; Coates et al., 2017) 
Allergen administration via the Solo® nebulizer using the volumetric method produced data 
to calculate the EAR PD20. If the maximum fall in FEV1 was ³ 20%, Formula 2.7 was used to 
interpolate EAR PD20 (Cockcroft et al., 1983): 




A1 = second to last dose of allergen administered 
A2 = last dose of allergen administered causing a fall in FEV1 ³ 20% 
R1 = the fall in FEV1 after A1 
R2 = the maximum fall in FEV1 after A2 occurring 10-minutes to 1-hour after inhalation 
If the maximum fall in FEV1 was < 20%, Formula 2.8 was used to extrapolate the EAR PD20 
(Jokic et al., 1998): 
Extrapolated EAR PD20 = [ $%&'()&*&	%	-'..	)/	012!	'-345	.'63	7864	]	𝑥	𝑙𝑎𝑠𝑡	𝑑𝑜𝑠𝑒	𝑜𝑓	𝑎𝑙𝑙𝑒𝑟𝑔𝑒𝑛	𝑎𝑑𝑚𝑖𝑛𝑖𝑠𝑡𝑒𝑟𝑒𝑑 
2.3 Measures of Inflammation 
Airway inflammation is central to asthma, making it an important variable to monitor in trials 
on asthma management therapies (Yokoyama et al., 2019). Various biomarkers of inflammation 
can provide non-invasive practical ways of monitoring the level of inflammation of the airways 
(Pawankar et al., 2009). These indirect measures, including levels of fractional exhaled nitric 
oxide and sputum differential cell counts, can serve as replacements for the invasive direct 
sampling measures including bronchoalveolar lavage and biopsy. 
 30 
2.3.1 Fractional Exhaled Nitric Oxide 
Nitric oxide (NO) has an established role in lung biology and the pathophysiology of 
respiratory disease (Dweik et al., 2011). NO can act as a vasodilator, mild bronchodilator, 
neurotransmitter and inflammatory mediator in the lungs and airways. The fraction of nitric 
oxide found in exhaled air (FeNO) can provide a biomarker of lower respiratory tract 
inflammation and is a beneficial procedure in respiratory research as it allows serial real-time 
measurements to monitor inflammatory status (Lieberman, 2007; Yokoyama et al., 2019). In 
uncontrolled asthmatics, high FeNO correlates with airway eosinophilia, a key component of 
allergic airway inflammation (Pawankar et al., 2009). However, FeNO is not specific for asthma 
as elevations in FeNO occur in non-asthmatic conditions including eosinophilic bronchitis, 
atopy, and allergic rhinitis (Global Initiative for Asthma, 2021). FeNO is closely associated with 
eosinophilic inflammation; however, raised FeNO does not accurately predict percentages of 
sputum eosinophils (Hastie et al., 2013). Therefore, FeNO measurements are a useful clinical 
tool in the diagnosis and phenotyping of asthma but cannot diagnose allergic asthma and 
eosinophilic inflammation alone.  
Elevated FeNO in allergic asthma is a result of increased production of NO by nitric oxide 
synthase (NOS) during the conversion of L-arginine into L-citrulline (Yokoyama et al., 2019). In 
the body, there are three identified isoforms of this enzyme that vary in their expression, 
localization, and molecular characteristics: neuronal NOS (nNOS), inducible NOS (iNOS) and 
epithelial NOS (eNOS). While all three isoforms can exist in the airways, nNOS and eNOS are 
constitutively expressed and activated by agonist-dependent increases in Ca2+ in the cytoplasm. 
Inflammatory cytokines stimulate production of mRNA for the inducible, Ca2+-independent form 
the enzyme, iNOS. iNOS has a greater capacity for NO production and a longer endurance, 
supplying a greater proportion of FeNO when activated. The inflammatory cytokines IL-4, IL-5 
and IL-13 are produced by activated Th2 cells, ILC2 and mast cells in the airways of asthmatic 
individuals. While NO is present in the exhaled air of healthy individuals, individuals with 
airway inflammation due to inflammatory cytokines would have a greater concentration of NO in 
their exhaled air. 
American Thoracic Society (ATS) guidelines define high FeNO indicating eosinophilic 
inflammation at levels > 50ppb (Dweik et al., 2011). Levels between 25-50ppb are considered 
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intermediate and should be interpreted with caution. A change in FeNO by 20% in an asthmatic 
when baseline levels are > 50ppb, or by 10ppb when baseline levels are £ 50pb is considered a 
significant change; however, there are not much data on the clinical significance of FeNO 
changes (Dweik et al., 2011). Following allergen inhalation, FeNO has been documented to 
increase by 7-hours and further increase by 24-hours in dual-responders (Kharitonov et al., 1995; 
Nomani et al., 2016). However, isolated early responders may show no significant increase in 
FeNO until at least 21-hours (Kharitonov et al., 1995). Immediately after allergen inhalation 
challenges, FeNO decreases; this is theorized to be caused by the concurrent changes in airway 
caliber (Haccuria et al., 2014). 
2.3.1.1  Method 
In the tiotropium allergic asthma study (Chapter 4), FeNO was measured with the NIOX Vero 
instrument (Circassia AB, UK). Measuring FeNO is reliant on a constant and maintained 
expiratory flow rate of approximately 50mL/s during the procedure (American Thoracic & 
European Respiratory, 2005). The flow rate dependence arises from the diffusion of NO from the 
airway wall into the lumen of the airways. FeNO measurements were comprised of an inhalation 
to TLC, followed by an exhalation at a flow rate around 50mL/s. The NIOX Vero instrument 
requires a 10-second-long exhalation to achieve a stable NO plateau from which the result is 
gathered. Mean plateau concentration over a 3-second window is the reported value in parts per 
billion (ppb). Two reproducible measurements were taken that did not vary more than 10% and 
the average was taken for analysis. 
2.3.2 Sputum Differential Cell Counts 
Eosinophil and neutrophil counts are reproducible biomarkers of airway inflammation. 
Increases in sputum eosinophils are evident within hours following allergen-induced 
exacerbations and in individuals with eosinophilic asthma (American Thoracic & European 
Respiratory, 2005). In healthy non-asthmatics, sputum differential cell counts are predominantly 
comprised of macrophages (Figure 2.2 Panel C) and neutrophils (Figure 2.2 Panel A), 
comprising approximately 43% and 50% of the total cell count, respectively (Bacci et al., 2004; 
Davidson et al., 2013). Sputum eosinophils (Figure 2.2 Panel B) are considered increased when 
they comprise > 3% of the proportion of cells in the sputum cell count, indicating eosinophilic 
inflammation. Increases in sputum airway inflammatory cells after allergen inhalation likely 
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reflects infiltration of the airway walls by these cells (Pin et al., 1992). Cellular infiltration can 
start as early as 2-hours after allergen and last up to 7-days, evidenced by bronchoalveolar lavage 
(Lam et al., 1987). Significant eosinophilia in the blood, sputum and bronchial lavage fluid of 
dual responders following allergen is well documented (De Monchy et al., 1985; Durham & Kay, 
1985; Lam et al., 1987; Pin et al., 1992). It is unclear whether this response occurs to the same 
magnitude in isolated early responders (De Monchy et al., 1985; Durham & Kay, 1985; Pin et 
al., 1992). Sputum eosinophil counts are a reproducible measurement often used to monitor 
inflammatory changes after allergen-inhalation (Boulet et al., 2007; Gauvreau et al., 1999). 
Although sputum eosinophils are often monitored in clinical trials on allergic asthma, airway 
basophils, mast cells and neutrophils may also increase after allergen (Gauvreau et al., 2000; 
Imaoka et al., 2011). 
Figure 2.1 Kwik Diff-stained sputum cells: neutrophils (Panel A), eosinophils (Panel B) and 
macrophages (Panel C).  
 
Table 2.2 Identification characteristics for sputum differential cell counts stained with Kwik Diff. 
Based on descriptions by Pizzichini et al. 
 
Cell Type Size Nucleus Kwik Diff Stain 
Eosinophils 9-15uM 2-lobed nucleus Reddish, pink 
Neutrophils 9-15uM 2-5-lobed nucleus Purple, pink 
Lymphocytes 8-16uM Round nucleus Pale blue 
Macrophage 14-30uM Multi-nucleated Blue, purple 
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2.3.2.1 Method 
In the allergic asthma study (Chapter 4), a dose of 200µg salbutamol was administered prior 
to sputum induction to prevent airway constriction (Pizzichini et al., 1996). An AeroEclipse® II 
nebulizer (Monaghan Medical, Plattsburgh, New York) was used to deliver hypertonic saline on 
continuous mode in increasing concentrations each for 7-minutes (7mL of 3%, 5%, and 7%). 
Following nebulization, participants blew their nose and rinsed out their mouth to avoid 
contamination from saliva and post-nasal drip. Participants were directed to cough and huff a 
sample from their chest into a sterile sample cup. At each concentration participants attempted to 
produce a sample and then performed a shortened spirometry maneuver to monitor for 
bronchoconstriction. Samples were processed within 2-hours of collection using a slightly 
modified method (Pizzichini et al., 1996). Mucus plugs were suspended in a volume of cold 
DPBS equal to 8 times the weight of the sample. The suspension was vortexed, rocked for 15-
minutes, vortexed again and then centrifuged (790g) at 4°C for 10 minutes. A volume equal to 4 
times the weight of the mucus plugs was drawn off, centrifuged (1500g at 4°C for 10-minutes) 
and the supernatant aliquoted and frozen for future research. A volume of 0.2% DTT equal to 4 
times the weight of the mucus plugs was added to the remaining cell suspension. The sample was 
then vortexed, rocked for 15-minutes and vortexed again before filtering. Using the tryptan blue 
exclusion method, total cell count and viability was determined from a 10uL aliquot using a 
haemocytometer. The sample was then centrifuged at 500g for 10-minutes, the supernatant was 
drawn-off and frozen for future research. The remaining cell pellet was resuspended in PBS to a 
cell concentration of 1.0x106 cells/mL. Duplicate cytospins were prepared using 40uL aliquots. 
The slides were stained with Kwik Diff (Thermo Scientific) and duplicate sputum differential 
cell counts (sDCC) were performed in a blinded fashion. Cells were identified based on 
established (Pizzichini et al., 1996) size, nuclei, and staining properties (Table 2.2).  
2.4 Methods Summary  
Clinical studies evaluating the safety and efficacy of asthma pharmacotherapies utilize a 
range of tools and procedures to monitor lung function and inflammatory status. These methods 
can provide insight into the pharmacodynamics of drugs in vivo. In the clinical studies described 
in Chapters 3 and 4, lung function and airway hyperresponsiveness were measured via 
spirometry and methacholine challenge testing, respectively. These methods were used in 
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Chapter 3 to monitor for the development of tolerance to bronchoprotection following regular 
use of a muscarinic antagonist, and in Chapter 4 they were used to follow baseline lung function 
to confirm the presence of asthma and assess asthma stability over the course of the study. The 
study outlined in Chapter 4 employed the allergen-inhalation challenge and measures of airway 
inflammation (FeNO and sDCC) to assess the efficacy of an inhaled muscarinic antagonist on 
airway responses to inhaled allergen.  
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3.0 REGULAR USE EFFECT OF INHALED IPRATROPIUM ON METHACHOLINE 
RESPONSIVENESS IN WELL-CONTROLLED ASTHMATICS 
3.1 Objectives 
The purpose of this study was to evaluate whether tolerance to the bronchoprotective effect 
occurred after regular use of ipratropium bromide. Additionally, this study sought to determine if 
rebound hyperresponsiveness to methacholine occurred following regular use of ipratropium 
bromide as found by Newcomb et al. This information could be used to inform clinical use and 
guide further research into muscarinic antagonist use in asthma. 
3.2 Hypothesis 
Methacholine-induced bronchoconstriction will decrease following daily use of ipratropium 
bromide and there will be an increase in methacholine responsiveness following treatment 
withdrawal. 
3.3 Relationship to Thesis 
This chapter describes the study evaluating methacholine responsiveness following the 
regular use of ipratropium bromide. This is an ‘Accepted Manuscript’ of an article published by 
Taylor & Francis Group in Canadian Journal of Respiratory, Critical Care, and Sleep Medicine 
on 25 August 2020, available online: https://doi.org/10.1080/24745332.2020.1799263.  
3.4 Abstract 
Rationale: Short-acting β2-agonists provide significant bronchoprotection to inhaled 
methacholine in individuals with asthma. Regular use of β2-agonists results in the development 
of tolerance to the bronchoprotective effect. Relatively little is known regarding the development 
of tolerance following regular use of short-acting muscarinic antagonists.  
Objectives: The current study was undertaken to assess bronchoprotection after regular use of 
inhaled ipratropium bromide (“ipratropium”) and after treatment withdrawal.  
Methods: Twelve adult participants with mild asthma were assigned to treatment in this 
double-blind randomized placebo-controlled crossover study. Ipratropium, 40µg thrice daily, and 
matching placebo were administered for 1 week (22 doses). Methacholine challenges were 
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performed at baseline, 30-minutes post first and last dose and 24-hours after the final dose. A 
minimum 7-day washout period separated the treatments.  
Measurements and Main Results: Significant bronchoprotection, measured as an increase in 
methacholine PD20 of 4.3 doubling doses (95% CI 3.62-5.06), occurred following the first dose 
of ipratropium. Bronchoprotection increased slightly to 4.5 doubling doses (95% CI 3.80-5.27) 
following regular use. Dose shifts following placebo were significantly lower at 0.23 (95% CI -
0.30-0.75) and 0.11 (95% CI -0.63-0.85) after the first and last dose respectively (p < 0.001 
versus ipratropium for both). Changes from baseline methacholine PD20 24-hours after treatment 
withdrawal were not significant between treatments (p = 0.19). 
Conclusions: Our data provide evidence that regular use of inhaled ipratropium does not result 
in loss of bronchoprotection or lead to rebound hyperresponsiveness following treatment 
withdrawal. Muscarinic antagonists appear to have a superior safety profile over β2-agonist use 
in the treatment of asthma.  
3.5 Introduction 
Asthma is a heterogenous respiratory disease characterized in part by airway inflammation 
and airway hyperresponsiveness to direct acting stimuli (e.g. methacholine). The 
bronchoconstriction associated with asthma can be treated with various bronchodilators that act 
on either adrenergic or muscarinic receptors. Most currently used adrenergic bronchodilators 
selectively bind β2 receptors of the airways to relax airway smooth muscle and induce 
bronchodilation. Muscarinic antagonists bind airway smooth muscle M3 receptors as the 
predominant mechanism for inhibition of bronchoconstriction. M3 receptors elicit airway smooth 
muscle contraction when stimulated by endogenous acetylcholine or inhaled MCh. MCh is a 
structural analog of ACh commonly used to induce bronchoconstriction in research and clinical 
settings. Muscarinic antagonists and β2-agonists elicit a bronchoprotective effect against MCh-
induced constriction via competitive or functional antagonism, respectively.  
Tolerance to the bronchoprotective effect following regular use of inhaled β2-agonists, 
including both the short-acting agonist salbutamol and the long-acting agonist, salmeterol has 
been well documented, (Bhagat et al., 1996; Boulet et al., 1998; Cheung et al., 1992; O'Connor et 
al., 1992) and occurs quite rapidly (Bhagat et al., 1995; Drotar et al., 1998; Stewart et al., 2012). 
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A decrease in the number of plasma membrane β2 receptors or “receptor downregulation” has 
been shown to play a role (Johnson, 2006). Tolerance to the vasoactive properties of various a- 
and b-adrenergic receptor antagonists via receptor upregulation, or an increase in receptor 
number following prolonged use, is common in the treatment of cardiovascular disorders 
(Aarons & Molinoff, 1982; Glaubiger & Lefkowitz, 1977; Vincent et al., 1992). Little is known, 
however, regarding the development of tolerance to inhaled muscarinic antagonists but receptor 
upregulation has been observed in other tissues, under different conditions (Emmelin, 1961; 
Friedman et al., 1983; Lee et al., 1975; Newcomb et al., 1985). The data showing changes in 
receptor densities following regular use of other drugs targeting G-protein coupled receptors 
together with evidence that supports muscarinic receptor upregulation suggest the possibility of 
receptor upregulation and subsequent loss of bronchoprotection following regular use of inhaled 
ipratropium. Despite the supportive data, a previous study in individuals with asthma failed to 
elicit a tolerance response to the bronchoprotective effect following regular high dose use of 
inhaled ipratropium but did document a transient rebound hyperresponsiveness to methacholine 
24-hours after treatment withdrawal (Newcomb et al., 1985). The outcomes of the previous study 
may have been influenced by study design. We therefore undertook the current investigation 
using standardized methodology and clinically indicated doses to assess the effect of regular use 
of inhaled ipratropium on both bronchoprotection and rebound hyperresponsiveness to 
methacholine in individuals with well-controlled asthma. 
3.6 Methods 
3.6.1 Participants 
Twelve non-smoking participants at least 18 years of age with well-controlled mild asthma 
were recruited. Participants were required to have stable lung function evaluated based on FEV1 
³ 65% of predicted and baseline methacholine PD20 £ 200µg. Participants were allowed to use 
salbutamol as a rescue bronchodilator, provided it was not used within 6-hours of a study visit. 
Daily inhaled corticosteroid use was also allowed if dosing was consistent and stable for at least 
4-weeks (n = 1). Individuals were ineligible if they had used a long-acting β-agonist or a 
muscarinic antagonist in the 30-days prior to the study. All other asthma controller or 
bronchodilator treatments were not allowed. Individuals also had to be devoid of any upper or 
lower respiratory tract infection for at least 4-weeks prior to study entry. In addition, individuals 
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were ineligible if they had been exposed to an allergen in the 4-weeks prior to the study, were 
pregnant or lactating, had diagnoses of diabetes or glaucoma or if they had cardiovascular, 
urinary, prostate or kidney problems. Written informed consent was obtained prior to performing 
any study related procedures. The study was approved by the University of Saskatchewan 
Biomedical Research Ethics Board and registered with clinicaltrials.gov as NCT#04167280. 
3.6.2 Methacholine Challenge Test 
The MCT, which includes spirometry, was performed as previously described (Chapter 2).  
3.6.3 Study Design 
The study followed a double-blind, randomized, placebo-controlled, crossover design. In 
randomized order, participants underwent a treatment period with the study drug, ipratropium, 
and a treatment period with a matching placebo. Treatment periods were separated by a 
minimum 7-day washout. During each treatment period, participants were required to take two 
puffs from the inhaler three times daily for seven days. The first dose and a final dose (dose #22) 
on Day 8 were administered in the laboratory. Four MCTs were performed during each treatment 
period; two on Day 1 (single dose effect), one on Day 8 (regular use effect) and one on Day 9 
(treatment withdrawal effect). The first MCT was used to determine eligibility and establish a 
baseline for the remainder of the treatment period. A 30-minute recovery period followed the 
first MCT prior to administration of the first dose. The second and third MCT’s commenced 30-
minutes after dosing. The final MCT was completed 24-hours after the final dose. All MCT were 
completed at the same time of day ± one hour. 
Table 3.1 Visit schedule. 


































































3.6.4 Study Drug and Blinding 
Kits comprised of one ipratropium inhaler (Atrovent®) and one placebo inhaler, both 
pressurized metered dose inhalers, were prepared by one of the investigators not involved in data 
collection. One of the two canisters was labelled as treatment 1 and the other as treatment 2. A 
randomization code was sealed in an envelope. Participant 1 received kit 1, treatment 1 first and 
treatment 2 second. Subsequent participants received subsequent kits in numerical order, each 
receiving treatment 1 first and treatment 2 second.  
3.6.5 Data Analysis 
Methacholine PD20 data were log transformed prior to analyses. Treatment effect was 
determined by calculating the dose shift in methacholine PD20 and reported as doubling doses. 
The following formula was used: dose shift = [(logPD20post-dose – logPD20baseline)/0.3] (O'Connor et 
al., 1992). Between treatment dose shifts and within treatment PD20 differences were compared 
using Student’s paired t-test (alpha 0.05) and Statistix 9 software (Analytical software, 
Tallahassee, Florida). A sample size of twelve participants provided a study power of >90% to 










3.7 Results  
3.7.1 Participants 
A total of 22 participants were enrolled in the study, 10 of which failed to meet methacholine 
PD20 inclusion criteria (i.e. had baseline methacholine PD20 £ 200µg). One participant with a 
baseline PD20 of 228.6µg was included in the investigation based on historical data (i.e. 
methacholine PD20 recently < 200μg) and on level of commitment to participating in a clinical 
trial (i.e. known to be reliable). Eleven participants followed the study to completion and one 
additional participant, the only participant using regular ICS (budesonide 200μg bid), was unable 
to finish treatment 2 (placebo) due to safety measures taken during the COVID-19 pandemic. 
(Table 1). No unexpected or serious adverse effects occurred. Mean baseline lung function and 
geometric mean methacholine PD20 data were similar for both treatments (Table 1). 
 
Table 3.2 Participant baseline demographics.  
Abbreviations: P#: participant number; FEV1: forced expiratory volume in 1 second; IB: 
ipratropium; MCh PD20: dose of methacholine causing a 20% fall in FEV1; [SD]; a Geometric 
mean; b 95% confidence interval. 
 













1 M 21 177.8 68.2 3.41 (78) 3.6 (83) 154.2 228.6
2 M 43 177.8 88.6 3.49 (84) 3.6 (87) 33.8 76.3
3 M 19 177.8 90.9 3.92 (91) 3.51 (81) 155 146.2
4 F 18 155 63.6 2.65 (99) 2.65(100) 149.5 102.6
5 M 73 167.6 65.9 2.02 (75) 2.03 (75) 28.9 35.9
6 M 35 195.6 84.5 4.95 (92) 4.93 (92) 56.5 38.4
7 F 23 162.1 65.9 3.45 (105) 3.66 (111) 10.0 15.3
8 M 18 177 59.1 4.21 (92) 4.2 (92) 196.4 74.9
9 M 22 166.9 68.2 3.59 (97) 3.57 (96) 89.7 100.0
10 M 29 172.7 79.5 3.86 (91) 4.1 (97) 63.6 136.2
11 M 28 175 70.5 3.42 (78) 3.38 (77) 155.1 183.9
12 F 19 172.3 71 3.46 (88) 3.49 (89) 69.0 123.0
Mean: 75% 29 172.3 71 3.46 (88) 3.49 (89) 72.4a 85.1a
M [16.3] [10.5] [10.8] [0.78] [0.78] 42-129b 51-138b
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3.7.2 Bronchoprotection, Tolerance and Rebound Hyperresponsiveness 
On average, single dose ipratropium (40µg) significantly decreased airway responsiveness to 
inhaled methacholine by 4.3 doubling doses (i.e. increased methacholine PD20 by more than 16-
fold) versus a doubling dose shift of 0.23 following placebo (p < 0.001) (Fig. 3.1). After seven 
days of regular use the magnitude of bronchoprotection increased slightly to 4.5 doubling doses 
following ipratropium and decreased slightly to 0.11 doubling doses following placebo (p < 
0.001 for ipratropium versus placebo) (Fig. 3.1). No rebound hyperresponsiveness was detected 
as dose shifts from baseline to 24-hours were -0.15 and 0.34 doubling doses following 
ipratropium and placebo withdrawal, respectively (p = 0.19) (Fig. 3.1). Individual methacholine 
PD20 at all time points for both treatments are shown in Figure 3.2. Geometric mean PD20 data 
are tabulated in Table 3.2. 
 
Table 3.3 Geometric mean methacholine PD20 (µg) data.a 













Figure 3.1 Dose shift (doubling dose) comparisons between ipratropium (IB) and placebo 
treatments after a single dose (40µg), regular dosing (40µg thrice daily for 7 days) and 24-hours 
after treatment withdrawal. IB data is a full data set (n=12); Placebo data set is n=12 for single 
dose and n=11 for regular dosing and 24-hour post treatment withdrawal. Sample size noted on 










Figure 3.2 Individual log methacholine PD20 data after single dose (2 puffs), regular dosing (2 
puffs thrice daily) and following treatment withdrawal (24-hours) for ipratropium (n=12, top) 
and placebo (n=11, bottom) treatments. 
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3.8 Discussion 
In our study of twelve mild well-controlled asthmatics, regular use of ipratropium did not 
result in tolerance to bronchoprotection or rebound hyperresponsiveness following treatment 
withdrawal. The literature in this area is sparse. We are aware of only one publication from 35-
years ago in which tolerance to methacholine induced bronchoconstriction and rebound 
hyperresponsiveness following regular use of ipratropium were studied (Newcomb et al., 1985). 
In this previous investigation, tolerance did not develop following regular use of high dose 
ipratropium (60μg four times daily for 3 weeks), however, transient rebound 
hyperresponsiveness was documented 24-hours after treatment withdrawal. A major limitation of 
the previous study was that the highest concentration of MCh administered was only 25mg/mL 
which was not high enough to elicit a 20% fall in FEV1 and generate a dose response following 
treatment. Failure to quantify maximal bronchoprotection to MCh may have skewed the results 
and underestimated the loss of bronchoprotection following regular use. Additional limitations of 
the previous study, include the absence of a placebo arm (possible bias due to not accounting for 
a placebo effect), the small sample size (potentially underpowered with only nine participants) 
and the use of dosimeter deep inhalation methodology (direct comparison with our current data 
may not be applicable due to different testing methodologies). Nonetheless, the findings of the 
previous study (3 puffs four times a day for three weeks; high dose) and our current study (2 
puffs three times a day for one week; low dose) suggest regular use of ipratropium does not 
result in loss of bronchoprotection to methacholine. Based on our knowledge of dose response 
and the development of tolerance following regular use of β2 agonists that is dose independent 
(Bhagat et al., 1996) and rapid onset (Bhagat et al., 1995; Drotar et al., 1998; Stewart et al., 
2012) we can infer a similar pattern may occur with muscarinic antagonists. These data suggest 
that increasing the dose or the duration of dosing with ipratropium are unlikely to result in the 
development of tolerance. This should be confirmed by prospective investigation.  
The absence of tolerance following regular use ipratropium is in stark contrast to the loss of 
bronchoprotection observed following regular use of both short and long acting β2-agonists. An 
early investigation by O’Connor et al showed a small but significant reduction in 
bronchoprotection against methacholine following 7-days of high dose terbutaline (O'Connor et 
al., 1992). Bhagat et al showed close to one doubling dose increase in methacholine 
responsiveness across all doses of salbutamol (200, 400 and 800µg) after one week of daily 
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treatment (Bhagat et al., 1996). Tolerance has also been shown following 8-weeks (Cheung et al., 
1992) and 4 weeks (Boulet et al., 1998) of twice daily salmeterol. Subsequent investigations 
documented the reduced efficacy to β2-agonist bronchoprotection to occur quite rapidly. In the 
case of salmeterol, statistically significant decreases of 44% and 37% in geometric mean 
methacholine PC20 occurred after just two 50μg doses (Bhagat et al., 1995; Drotar et al., 1998); 
with twice daily salbutamol (200µg q12h) loss of bronchoprotection was observed after just 7 
doses (i.e. 3.5 days) (Stewart et al., 2012). As a side note, the addition of inhaled corticosteroids 
(ICS) as a preventative measure against the loss of bronchoprotection proved ineffective 
following salmeterol use (Boulet et al., 1998; Kalra et al., 1996) but beneficial, ex vivo, 
following salbutamol use (Cooper & Panettieri, 2008). Recent clinical trial data obtained from a 
larger sample challenges the previous negative findings not only with respect to the beneficial 
effects of concomitant ICS but also to the prevalence of tolerance and the role of b2 receptor 
downregulation as a potential mechanism (Cardet et al., 2019). One participant in our study was 
using ICS and this individual produced data consistent with that of the study cohort (i.e. 
significant single dose bronchoprotection that was sustained after regular use and a slight 
increase in response 24-hours after treatment withdrawal) suggesting that concomitant ICS use 
would be unlikely, and not expected, to alter our observed study outcome. 
Our findings are inconsistent with the Newcomb study data in that we did not observe 
rebound hyperresponsiveness to methacholine following treatment withdrawal. A possible 
explanation for the contradictory findings between our current study and the previous study may 
be attributed to differences in dosing as a higher dose for a longer duration (60µg given four 
times daily for 3-weeks compared to our study design of 40µg given three times daily for 1-
week) may have led to a state of supersensitivity following treatment withdrawal.  
The absence of the development of tolerance in our study suggests muscarinic receptor 
upregulation did not occur following one week administration of clinically relevant dosing of 
ipratropium. Given that receptor upregulation is a well-documented phenomenon following 
prolonged antagonism such as occurs after chronic use of adrenergic receptor antagonists 
(Aarons & Molinoff, 1982; Glaubiger & Lefkowitz, 1977; Vincent et al., 1992) and with 
evidence that muscarinic receptor upregulation occurs in non-lung tissue (Emmelin, 1961; 
Friedman et al., 1983; Lee et al., 1975); and given that receptor downregulation occurs both 
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quickly and at clinically relevant doses with β2-agonists within the lung, it is unclear why loss of 
bronchoprotection to methacholine was not observed in our investigation. One possible 
explanation could be poor dosing compliance as ipratropium was self-administered for doses 2 
through 21. However, we verbally confirmed dosing compliance with participants following 
regular dosing (i.e., in the laboratory prior to administration of the final dose) and no participant 
reported any missed doses. Another possible and important consideration for a negative study is 
that of sample size or study power. We can rule this out as well as a sample size of 12 
individuals provides a study power of 90% to detect a one dose difference in methacholine PD20 
(Inman et al., 1998). 
Our findings are limited to clinical data and any mechanistic effects can only be inferred. 
Evidence has shown that receptor antagonism with some b-blockers does not lead to receptor 
upregulation and can lead to a decrease in receptor density (Brodde et al., 1986). Another 
relatively new phenomenon is that of biased antagonism, where the receptor is blocked in a 
competitive manner but intracellular signalling pathways responsible for regulating receptor 
numbers (i.e. β arrestin activity) are not affected (Hitchinson et al., 2018). Given the promising 
data that biased antagonists have produced, one wonders if a similar strategy (i.e. biased 
agonism) toward β2 receptors in the lung would prove beneficial in preventing tolerance but 
maintaining the excellent bronchoprotective and bronchodilatory properties. While these 
mechanistic data are intriguing, the relevance to explaining the possible mechanistic rationale for 
the absence of tolerance following ipratropium use is limited (i.e. intrinsic sympathomimetic 
activity and small peptide molecules). Ex vivo muscarinic M3 receptor binding assays using 
human lung tissue would be one method for determining whether receptor upregulation occurs 
on airway smooth muscle following prolonged ipratropium use. Consideration might also be 
given to the non-selective receptor binding properties of ipratropium and the potential role 
concomitant antagonism of muscarinic subtypes 1 and 2 may play in regulating M3 receptor 
numbers. Given the class effect on the development of tolerance following regular use of β2 
agonists (i.e. loss of bronchoprotection occurs with both short and long-acting β-agonists) a 
clinical investigation on loss of bronchoprotection following regular use of tiotropium may 
provide additional insight. Although anticipated to also be a negative study based on β2 agonist 
data, prolonged receptor occupancy and receptor specificity for the M3 subtype are rationale 
supporting a different outcome. 
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With respect to asthma, ipratropium is only indicated for acute use in the management of 
exacerbations, therefore, potential clinical implications from our findings relate to off label use 
in the routine management of asthma and, indirectly, to use in COPD where treatment with 
anticholinergics is both recommended and commonly used. In light of the well-documented 
detrimental effects of regular β2-agonist use in the treatment of asthma, it may be useful to 
further investigate, or perhaps renew our interest in the mechanisms and clinical effects of 
targeting the cholinergic system and the use of muscarinic antagonists as alternative treatments.  
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4.0 TIOTROPIUM EFFICACY AGAINST ALLERGEN INDUCED EARLY 
ASTHMATIC RESPONSES 
4.1 Objective 
The primary objective was to determine if regular tiotropium affects allergen-induced early 
asthmatic responses. Our secondary objective was to use indirect measures of airway 
inflammation to assess if tiotropium influences airway inflammation (i.e. Th2 phenotype).  
4.2 Hypothesis 
 Tiotropium will attenuate allergen induced airway responses by blocking M3 receptors and 
disrupting ACh-TSLP synergism that is promoting the Th2 phenotype in allergic asthma.  
4.3 Relationship to Thesis 
This chapter describes the study on allergen responsiveness and inflammation following 
regular tiotropium. This manuscript will be submitted for publication.  
4.4 Abstract 
Rationale: Acetylcholine promotes an allergic or type 2 response via muscarinic receptors on 
dendritic cells. Single dose SAMA show equivocal results on allergen-induced asthmatic 
responses. The effect of LAMA, such as tiotropium bromide monohydrate (Spiriva® 
Respimat®), on allergen-induced asthmatic responses is unknown.  
Objectives: The study aimed to assess the efficacy of regular use tiotropium against allergen-
induced early asthmatic responses and airway inflammation. 
Methods: Thirteen adult participants with mild allergic asthma were assigned to treatment in this 
double-blind, randomized, placebo-controlled crossover study. Tiotropium, 5µg once daily, and 
matching placebo were each administered for 7-days. Allergen inhalation challenges were 
performed 30-minutes following the final dose on Day 8. Measures of airway inflammation 
(FeNO and sDCC) were collected at baseline, before allergen inhalation (FeNO only), and 5-
hours after allergen inhalation. A minimum 14-day washout separated the treatment periods. 
Measurements and Main Results: Regular use of tiotropium worsened the early asthmatic 
response to allergen as evidenced by a decrease in EAR PD20 from a geometric mean of 22.2 
allergen units (SE = 0.14) following placebo treatment to 16.7 allergen units following 
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tiotropium treatment (p = 0.054). No significant difference in the level of FeNO was observed 
following tiotropium treatment. The allergen induced increase in sputum eosinophils was also 
unchanged following tiotropium treatment; sputum eosinophils increased by 14.5% and 15.2% 
for tiotropium and placebo treatments, respectively (p = 0.91) 
Conclusions: Our data suggest regular use of tiotropium does not alter airway responses to 
inhaled allergen in mild atopic asthmatics. A trend toward a worsening of the early asthmatic 
response was observed although this did not coincide with a trend toward worsened airway 
inflammation. Data surrounding the efficacy of muscarinic antagonists on allergen induced 
responses remains inconclusive. 
4.5 Introduction 
There are accumulating data on the role of non-neuronal cholinergic signalling in allergic 
airway responses (Gori et al., 2019; Gori et al., 2017; Kawashima, 2004; Koyama et al., 1998; 
Masini et al., 1985; Reinheimer et al., 1997). Signalling at non-neuronal muscarinic receptors 
seems to mediate a proinflammatory signal (Gori et al., 2019). Gori et al demonstrated ACh 
polarizes dendritic cells towards a type-2 promoting profile via the M3 muscarinic receptor (Gori 
et al., 2019; Gori et al., 2017). Therefore, inhaled muscarinic antagonists may protect the airways 
by inhibiting ACh-induced polarization. Data from ovalbumin challenged animals treated with 
muscarinic antagonists show reductions in allergen-induced changes (Bos et al., 2007; Ohta et 
al., 2010). In a recent ex vivo dendritic cell investigation, synergism between ACh and the 
epithelial cytokine, TSLP, in promoting type 2 responses was shown and effectively inhibited by 
muscarinic antagonism (Gori et al., 2017). Data documenting anti-TSLP efficacy in the human 
allergen challenge model shows a significant but not complete reduction in allergen-induced 
changes (Gauvreau, Hohlfeld, et al., 2020; Gauvreau et al., 2014). The residual response could 
be due to intact cholinergic signalling on dendritic cell muscarinic receptors. However, pro-
inflammatory cholinergic signalling is not conserved amongst all cells involved in immune 
responses. By contrast, ACh appears to modulate mast cell degranulation via the M1 muscarinic 
receptor, partially inhibiting the release of bronchoconstricting mediators (e.g. histamine and 
cysteinyl leukotrienes) (Reinheimer et al., 1997; Reinheimer et al., 2000). Based on these 
conflicting data it is unknown whether airway muscarinic antagonism would have anti-
inflammatory or pro-inflammatory effects on allergen-induced airway responses. While SAMA 
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efficacy against allergen-induced constriction has been evaluated (Clarke et al., 1982; Cockcroft 
et al., 1978; Fish et al., 1977; Howarth et al., 1985; Itkin & Anand, 1970; Orehek et al., 1975; 
Ruffin et al., 1978; Yu et al., 1972), there are no human data on long-acting formulations. 
Tiotropium bromide (Spiriva® Respimat®) is the only LAMA currently approved in the 
management of asthma, with affinity for both M1 and M3 muscarinic receptors. Collectively, 
these data suggest that the effects of LAMA on allergen-induced airway responses should be 
evaluated in the human allergic asthma model.  
Asthma is a chronic respiratory disease characterized by reversible airway obstruction, airway 
inflammation, hyperresponsiveness to stimuli and airway remodelling. A major environmental 
factor involved in asthma development is allergen exposure. In sensitized individuals, allergen 
induced cellular responses lead to type 2 inflammation and bronchoconstriction that can manifest 
shortly after allergen exposure, known as the allergen-induced EAR. A portion of allergic 
asthmatics may experience recurrence of bronchoconstriction 3-8 hours after allergen, known as 
the LAR. Individuals who experience both early and late responses to allergen are dual 
responders. Both early (Davis et al., 2005) and late (Davis et al., 2009) bronchoconstriction 
responses to allergen are due to release of histamine and CysLTs. Late responses are associated 
with increased airway inflammation and recruitment of effector cells, most predominantly 
eosinophils (Gauvreau et al., 2015). The allergen inhalation challenge has become an important 
tool for studying pharmacological modulation of allergic airway responses. The magnitude of 
allergen-induced inflammation can be indirectly quantified using measures of FeNO and sDCC 
of inflammatory cells. Using standardized methodology, we therefore undertook this 
investigation to assess the effect of regular inhaled tiotropium on both allergen-induced 




Eligible participants had well-controlled mild allergic asthma, were non-smoking and between 
18-65 years old. Stable baseline lung function was required for study enrollment and FEV1 had 
to be ≥ 80% of predicted. Asthma management had to require less than daily use of short-acting 
b2 agonist for occasional symptoms. Individuals were ineligible for study enrollment if they 
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required current use of regular inhaled corticosteroids, inhaled muscarinic antagonists, 
combination therapy, biologics, leukotriene receptor antagonists or antihistamines to manage 
asthma and/or allergy. Participants were required to have a positive response to inhaled MCh 
with MCh PD20 being £ 400µg. Atopy was evidenced by a positive skin prick test to at least one 
of three common allergens and a clinical history of asthma symptom development upon 
exposure. Participants were required to have not been exposed to allergen in the 4-weeks prior to 
beginning the study. Participants were required to be free of respiratory infection for 4-weeks 
prior to study entry. In addition, any recent travel, symptoms of COVID-19 or known exposure 
to a positive COVID-19 case required a 14-day interval prior to study visits. Individuals were 
excluded for the following medical conditions: pregnancy, current breast-feeding, narrow angle 
glaucoma, urinary retention or known hypersensitivity to tiotropium bromide or Spiriva® 
Respimat® formulation components. Use of non-steroidal anti-inflammatory medications was 
prohibited for 3-days prior to any study visit, and salbutamol use was prohibited within 6-hours 
of a study visit. Written informed consent was obtained at study visit 1 prior to any procedures. 
This study was approved by the University of Saskatchewan Biomedical Research Ethics Board, 
registered with clinicaltrials.gov as NCT#04648813 and received no objection from Health 
Canada.  
4.6.2 Study Design 
This study followed a randomized double-blind placebo-controlled crossover design. 
Participants were randomly assigned to receive tiotropium or a matching placebo during the first 
treatment period with a minimum 14-day washout separating the two periods (Table 4.1). At the 
first study visit, atopy to study allergens was established using a skin prick test and skin titration 
endpoint. The initial visit for each treatment period consisted of a baseline methacholine 
challenge to monitor non-specific airway responsiveness, and baseline indirect measurements of 
inflammation by the fraction of exhaled nitric oxide (FeNO), and sputum differential cell counts 
(sDCC). The first dose was administered at the end of the initial study visit following an 
inhalation technique tutorial for the use of a Spiriva® Respimat® device. Participants were 
instructed to self-administer daily doses (i.e. doses #2-#7) at roughly the same time of day. The 
final dose (dose #8) was administered in the laboratory following baseline spirometry. Thirty-
minutes later, a pre-allergen FeNO measurement was taken, and spirometry was repeated. An 
allergen inhalation challenge commenced as previously described (Cockcroft et al., 2019). The 
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FEV1 recovery following allergen was measured at timed intervals up to 5-hours. After 5-hours, 
inflammatory measures were re-examined using FeNO and sDCC. 
Table 4.1 Visit schedule. 
Abbreviations: FeNO: fractional exhaled nitric oxide; MCT: methacholine challenge test; SPT: 
skin prick test; STE: skin test endpoint titration; TX: treatment; AIC: allergen inhalation 
challenge.  
4.6.3 Laboratory Procedures 
All procedures including spirometry, SPT, STE, MCT, AIC, FeNO, sputum induction and 
sDCC were performed as previously described (Chapter 2). 
4.6.4 Study Drug and Blinding  
One investigator not involved in data collection prepared kits of one tiotropium Respimat® 
inhaler (Spiriva® Respimat®) and one matching placebo Respimat® inhaler. Placebo treatments 
were provided by Boehringer Ingelheim, and active treatments were sourced from the pharmacy 
at Saskatoon Royal University Hospital. One inhaler was labelled treatment #1, the other 
treatment #2 and the randomization code was sealed in an envelope. Participant 1 received kit 1 
and subsequent kits were supplied in numerical order. Each participant received treatment #1 
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4.6.5 Data Analysis 
EAR PD20 and FeNO data were log transformed prior to analyses. Treatment effect on the 
EAR was determined by differences in placebo EAR PD20 and tiotropium EAR PD20 Treatment 
effect on FeNO was compared by the difference in FeNO data at baseline to 1-week of treatment 
and at pre-allergen (after 1-week of treatment) to 5-hours post-allergen. Treatment effect on the 
percent of sputum eosinophils was expressed as the difference in percent sputum eosinophils at 
baseline to 5-hours post-allergen compared for tiotropium versus placebo treatments. Treatment 
differences were evaluated with Student’s paired t-test (alpha 0.05) and Statistix 9 software 
(Analytical software, Tallahassee, Florida). A sample size of thirteen participants provided a 
study power of > 90% to detect a 50% difference in EAR PD20 (Inman et al., 1995). A post hoc 
non-parametric sign test was used to confirm or refute the paired t-test. A sample size of 8 
participants provided a study power of 85% to detect a 35% attenuation of percent sputum 













4.7 Results  
4.7.1 Participants 
 A total of fifteen participants were enrolled in the study. However, two participants were 
ineligible to continue the study due to a negative skin prick test (i.e. absence of atopy to available 
allergens) or due to the absence of an asthmatic response to inhaled allergen at visit 2. One 
participant with historical allergic data only achieved a fall in FEV1 of 12.8% following allergen 
inhalation and no further doses were administered due to strong cough response causing 
discomfort. Thirteen participants followed the study to completion. No unexpected or serious 
adverse events occurred. Baseline mean FEV1 and geometric mean methacholine PD20 data were 
similar for the two treatment periods (Table 4.1). 
 
Table 4.2 Participant baseline demographics. 
Abbreviations: P#: participant number; FEV1: forced expiratory volume in 1 second; Tio: 
tiotropium; MCh PD20: dose of methacholine causing a 20% fall in FEV1; T Grass: timothy 
grass; HDM DP: house dust mite dermatophagoides pteronyssinus; [SD]; a Geometric mean; b 
















1 M 44 177.8 90.7 3.44 (84) 3.49 (85) 83.1 69.8 Cat hair
2 M 29 170.2 79.4 3.95 (97) 3.66 (90) 74.7 111.7 Cat hair
3 M 20 177.8 99.8 3.72 (80) 3.77 (81) 144.0 208.3 Cat hair
4 F 21 165.1 74.8 3.37 (98) 3.56 (101) 1,159.4 503.1 HDM DP
5 M 22 170.2 70.3 3.77 (97) 3.72 (96) 78.9 65.8 Cat hair
6 F 34 160.0 63.5 2.85 (94) 2.86 (94) 467.8 90.3 T grass
7 M 52 193.0 117.9 3.99 (86) 3.70 (80) 41.8 38.0 Cat hair
8 F 25 172.8 63.5 3.43 (92) 3.30 (88) 27.0 8.8 Cat hair
9 F 42 167.6 106.6 3.02 (96) 2.88 (91) 583.4 217.4 Cat hair
10 M 39 173.0 83.9 3.72 (93) 3.67 (92) 791.6 384.1 HDM DP
11 F 25 163.0 49.0 2.84 (86) 2.87 (87) 24.3 17.7 HDM DP
13 F 22 167.6 73.9 3.29 (108) 3.12 (103) 23.4 186.9 Cat hair
14 M 30 168.9 79.8 3.76 (94) 3.27 (82) 118.0 221.7 HDM DP
Mean: 54% 31 171.3 81.0 3.47 (93) 3.37 (90) 122.1a 100.0a ___
M [10.2] [8.3] [19.0] [0.39] [0.35] 54-278b 49-204b
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4.7.2 Early Asthmatic Response 
Contrary to the hypothesis, regular tiotropium trended towards increased allergen 
responsiveness (i.e. lower PD20) during the early asthmatic response with borderline statistical 
significance (p = 0.054). EAR PD20 decreased from a geometric mean of 22.2 allergen units (SE 
= 0.14) with placebo to 16.7 allergen units with tiotropium (SE = 0.14) (Fig. 4.1). Increased 
allergen responsiveness occurred in ten of thirteen participants with two participants showing a 
decrease in EAR PD20 greater than 1-doubling dose. The remaining three participants showed 















Figure 4.1 Individual and geometric mean EAR PD20 data after placebo and tiotropium (5µg 
once daily) treatments.  
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4.7.3 Inflammatory Measures 
The difference in geometric mean FeNO levels did not change from baseline after 1-week of 
tiotropium treatment compared to placebo (p = 0.29). The difference in FeNO levels from pre-
allergen challenge levels (after 1-week of dosing) to 5-hours post allergen challenge also did 
not significantly differ between treatment periods (p = 0.19). Regular use of tiotropium resulted 
in an increase in FeNO by 5.4ppb compared to 1.2ppb with placebo treatment (Table 4.3). 
FeNO levels decreased 5-hours after allergen inhalation in both treatment groups with a mean 
2.2ppb decrease following tiotropium and a 4.2ppb decrease following placebo (Table 4.3).  
 
Table 4.3 Comparison of the geometric mean fractional exhaled nitric oxide (ppb) levels at 
various timepoints for placebo and tiotropium treatments.  












Eight of thirteen participants were able to produce sputum. In these individuals, the percent 
of sputum eosinophils increased following allergen inhalation for both placebo and tiotropium 
treatment (Fig. 4.2) with no significant difference between the two (p = 0.91). Sputum 
eosinophils increased significantly after allergen inhalation by 14.5% (p = 0.01) and 15.2% (p = 
0.002) for tiotropium and placebo treatments, respectively. 
 
Figure 4.2 Mean percent of sputum eosinophils in a differential count of 400 cells at baseline 

























In our study of thirteen well-controlled mild allergic asthmatics, daily use of tiotropium led to 
a non-significant increase in the early asthmatic response to inhaled allergen with no significant 
effect on levels of FeNO or allergen induced sputum eosinophilia. However, use of Student’s 
paired t-test to evaluate the early asthmatic response assumes that the data are normally 
distributed. Since EAR PD20 for tiotropium versus placebo treatments is nearly statistically 
significant (p = 0.054), and only three of thirteen participants show a different response (slight 
decrease in allergen responsiveness) it is possible that the data are not normally distributed, and 
these participants may be outliers. For this reason, we chose to perform a non-parametric 
analysis of allergen responsiveness (EAR PD20) to confirm or refute the trend observed. A post 
hoc sign test supported the trend towards increased allergen responsiveness after regular 
tiotropium with significance (p = 0.046). 
 The effect of single and regular dosing of LAMA on allergen induced asthmatic responses 
was previously unknown. However, there have been many investigations on single dose SAMA 
efficacy against allergen induced asthmatic responses. For the most part, these data demonstrate 
partial efficacy for inhaled SAMA against allergen-induced responses in a portion of allergic 
asthmatics (Clarke et al., 1982; Cockcroft et al., 1978; Orehek et al., 1975; Ruffin et al., 1978; 
Yu et al., 1972). However, SAMA shows no attenuation of the early response in another subset 
of allergic asthmatics (Fish et al., 1977; Howarth et al., 1985; Itkin & Anand, 1970). Therefore, 
there may be pathophysiologic differences among allergic asthmatics that predisposes some to 
better protection against allergen with SAMA. The results of this study suggest this efficacy is 
not conserved with LAMA as regular tiotropium did not attenuate and potentially worsened the 
early asthmatic response. While a small proportion (3 participants) of the study population 
showed less response to allergen with tiotropium, the magnitude (< half of a doubling dose) 
suggests this may be due to natural variation in allergen responsiveness and not a drug effect. 
 It is unknown whether a single dose of tiotropium would demonstrate increased allergen 
responsiveness. Data from ovalbumin-challenged animals show promising efficacy of single 
dose tiotropium against allergen-induced asthmatic responses (EAR and LAR) (Raemdonck et 
al., 2012; Smit et al., 2014). Clinical investigations with single dose SAMA show no efficacy 
against allergen-induced LAR (Cockcroft et al., 1978). Single dose tiotropium may also increase 
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allergen responsiveness, similar to regular tiotropium treatment. However, it cannot be ruled out 
that regular use of tiotropium may have induced the increased responsiveness to allergen similar 
to regular b2-agonist use (Cockcroft et al., 1993; Cockcroft et al., 1995). Salbutamol, dosed 
200µg four times daily for 2-weeks significantly increased the EAR by approximately two-fold. 
At the same dose for 1-week, salbutamol enhanced the LAR causing the maximum fall in FEV1 
to nearly double (Cockcroft et al., 1995). These detrimental effects coincide with tolerance to the 
bronchoprotective effect of salbutamol against constriction induced by methacholine, adenosine 
monophosphate and histamine, that occur with both short and long-acting formulations (Jokic et 
al., 2001; Vathenen et al., 1988). However, single doses of LABA and SABA are effective at 
inhibiting allergen-induced asthmatic responses (Eiser, 1991; Howarth et al., 1985; Ruffin et al., 
1978; Weersink et al., 1994). We recently demonstrated that regular use of ipratropium bromide 
(SAMA) for 1-week did not produce tolerance to the bronchoprotective effect against 
methacholine (Cropper et al., 2020). Similar to b2 agonists, it is expected that this finding is a 
class effect and may be conserved with regular tiotropium use. However, one previous study 
with higher doses of ipratropium for a longer duration reported significant hyperresponsiveness 
to methacholine 24-hours after treatment withdrawal (Newcomb et al., 1985). Perhaps regular 
use of a muscarinic antagonist that stays bound to airway muscarinic receptors longer, such as 
tiotropium, may lead to bronchoprotective tolerance and enhanced allergen responsiveness.  
An alternative explanation for the increased allergen responsiveness observed following 
tiotropium treatment could be enhanced mast cell degranulation as mast cells are the 
predominant source of bronchoconstricting mediators during the EAR. Reinheimer et al 
identified inhibitory M1 muscarinic receptors on mast cells in isolated human bronchi 
(Reinheimer et al., 2000). Acetylcholine release from proximal non-neuronal cells onto mast 
cells inhibits histamine release via M1 stimulation (Reinheimer et al., 1997). In vitro lung tissue 
investigations have shown both enhanced histamine release and no effects with muscarinic 
antagonist treatment (Kohno et al., 1989; Reinheimer et al., 1997). Despite being kinetically 
selective for M3 receptors, tiotropium retains significant binding affinity for the M1 receptor with 
a dissociation half-life of 10.5-hours (Kistemaker & Gosens, 2015). The EAR may have been 
slightly enhanced by tiotropium with the removal of cholinergic inhibition on mast cells. 
Enhanced mast cell degranulation is thought be involved in the significant worsening of 
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asthmatic responses to allergen with regular b2-agonist use (Cockcroft et al., 1993; Cockcroft et 
al., 1995). The slight increase in allergen responsiveness with tiotropium could be due to a 
balancing of beneficial anti-inflammatory effects and detrimental effects on mast cells. It is 
theorized that antagonism of the M3 receptor on dendritic cells would attenuate acetylcholine-
enhanced polarization of dendritic cells to a type 2 promoting profile (Gori et al., 2019; Gori et 
al., 2017). The epithelial cytokine, TSLP, also demonstrates polarization of dendritic cells to a 
type 2 profile that promotes maturation of CD4+ T helper Type 2 lymphocytes. In contrast to 
tiotropium, anti-TSLP biologic therapy is clinically efficacious against allergen-induced 
asthmatic responses, eosinophil recruitment and reduces exhaled nitric oxide levels (Gauvreau, 
Hohlfeld, et al., 2020; Gauvreau et al., 2014). Tiotropium was theorized to elicit similar 
beneficial effects against allergen-induced responses. However, if acetylcholine modulates mast 
cell degranulation in addition to its proinflammatory role on dendritic cells, muscarinic 
antagonism of these dual functions could elicit neither a beneficial or detrimental effect, as seen 
(slight effect observed rather than strong inhibition or enhancement). This explanation relies 
heavily on data from animal model investigations on the non-neuronal cholinergic signalling 
system which does not always translate to in vitro human lung tissue findings, therefore this 
interpretation is cautioned (Kohno et al., 1989; Reinheimer et al., 2000). Unfortunately, the 
present study findings are limited to clinical data, and we can only infer mechanistic effects. 
The trend toward increased allergen responsiveness following tiotropium treatment is further 
supported by analysis of the maximum fall in FEV1 and FEV1 recovery from allergen (i.e. 
progression to a late response). When the dose of allergen administered is kept constant, the 
maximum percent fall in FEV1 is reproducible for the EAR and LAR (Inman et al., 1995). The 
primary endpoint of the present study was EAR PD20, and it was not required to keep the dose of 
allergen administered constant; a benefit of performing an EAR investigation (i.e. the ability to 
quantitate a dose response following pharmacological intervention). However, in the current 
investigation six participants responded slightly differently to the same dose of allergen after 
treatment. The mean maximal fall in FEV1 in these individuals was 23.8% with tiotropium and 
20.5% with placebo treatment providing a signal, albeit weak, to a worsened response to allergen 
following tiotropium pre-treatment. Tiotropium treatment also appears to cause a trend towards 
LAR development, largely influenced by two participants. These two participants experienced 
decreases in FEV1 of 15.2% and 15.6% with tiotropium and only a 9.9% and 0.3% fall with 
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placebo, respectively. Based on these observations, the effect of tiotropium treatment on 
allergen-induced late asthmatic responses be further investigated. 
The effect of tiotropium on allergen-induced inflammation remains inconclusive. 
Interpretation of these data is cautioned as only six participants received the same dose of 
allergen and allergen-induced inflammatory responses may be dose-dependent (Cockcroft & 
Davis, 2008). Five of eight sputum producers received different doses of allergen, all receiving 
less allergen during the tiotropium treatment period. Therefore, the slight differences in mean 
sputum eosinophils observed between the two treatments could be partially due to the dose of 
allergen. While late inflammatory sequelae are associated with the LAR, our pilot study aimed to 
observe a signal for anti-inflammatory efficacy of tiotropium at 5-hours after allergen. This study 
recruited all-comers with early responses, including dual responders. Therefore, the study 
population may not have much underlying allergic and eosinophilic inflammation, as 
demonstrated by a low/normal (< 25ppb) to intermediate (25-50ppb) mean baseline FeNO 
around 30ppb (Table 4.2) (Dweik et al., 2011). Although, sputum differential cell counts from a 
portion (8 participants) of the study population show relatively high eosinophilia (> 3% of total 
cell counts) (Figure. 4.3), at least two were suspected dual responders based on the present study 
and historical laboratory data. However, significant increases in sputum eosinophils after 
allergen were replicated in isolated early responders at 5-hours after allergen. This further 
supports the caution of extrapolated non-neuronal cholinergic animal model data as tiotropium 
has been shown to attenuate eosinophil infiltration after allergen in various ovalbumin challenge 
animal models (Bos et al., 2007; Bosnjak et al., 2014; Kang et al., 2012). John-Schuster et al 
found no change in eosinophil infiltration with tiotropium and in M3-knockouts following house 
dust mite challenge in mice and explained the contradictory findings from use of a human-
relevant allergen (John-Schuster et al., 2017). In our study, tiotropium did not inhibit allergen-
induced eosinophil infiltration, suggesting that modulation of DC-polarization was not 
significant enough to reduce proinflammatory cytokines involved in the recruitment of 
eosinophils. This theory could be supported by immunohistochemistry analysis of sputum 
samples to quantify proinflammatory cytokine levels. Sputum samples from the present study 
will be stored for future investigation to confirm or refute this theory.  
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 FeNO levels stayed constant throughout the study during both treatments, despite 
allergen inhalation. It is well documented (Gauvreau et al., 2014; Nomani et al., 2016; Rolla et 
al., 2011; Taylor et al., 1998) that FeNO is increased at 7- and 24-hours after allergen inhalation 
for dual and isolated late responders. However, Taylor et al found a trend towards increased 
FeNO as early as 2-hours after allergen in dual responders. Isolated early responders may not 
exhibit significant increases in FeNO until 21-hours after allergen (Kharitonov et al., 1995). The 
trend towards decreased FeNO at 5-hours after allergen in our study may be explained by 
reduced airway calibre following allergen as bronchoconstriction has been shown to decrease 
FeNO following bronchoprovocation challenges (Haccuria et al., 2014; Tadaki et al., 2009). The 
non-significant trend towards increased FeNO after 1-week of tiotropium treatment by 5.4ppb 
compared to an increase of 1.2ppb with placebo may suggest increases in underlying 
inflammation prior to the allergen-inhalation challenge. If this is the case, sputum differential 
cell counts at baseline and after regular tiotropium could provide more insight into inflammatory 
status with regular tiotropium use.  
A study limitation that could have affected the outcome was unobserved administration of 
treatment doses #2-#7 by participants outside of the laboratory. If doses of tiotropium treatment 
were missed, the drug effect could be underestimated. However, at the final visit of each 
treatment period, all participants verbally stated no doses were missed. This was supported by a 
slight but non-significant mean increase in FEV1 for the study population after 1-week of 
tiotropium treatment, prior to the final treatment dose (Table 4.4) that was significantly different 
from placebo treatment.  
Table 4.4 Mean FEV1 (L) at baseline and after tiotropium versus placebo treatment. 
Abbreviations: Tx: treatment; [SE]; *within tiotropium treatment significance: p < 0.02 
compared to baseline and 1-week Tx timepoints; **within placebo treatment significance: p < 
0.01 compared to baseline; Between treatment significance occurred between the 1-week Tx 
timepoint (p = 0.03) and 30-minutes after the final dose (p = 0.02) for tiotropium versus placebo 
treatment.  
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 Bronchodilation from tiotropium in the well-controlled mild allergic asthmatic population 
was found in the present study, outside of study endpoints (Table 4.4). Significant 
bronchodilation was seen 30-minutes following the final dose of tiotropium by 180mL from 
baseline (p = 0.02) and 90mL (p = 0.01) from the pre-dose levels. This effect did not occur 
following placebo treatment. However, a slight but significant (p < 0.01) decline in mean FEV1 
of 110mL occurred following 1-week of placebo treatment. FEV1 improvement in this 
population aligns with the beneficial lung function improvements seen in severe asthmatics when 
tiotropium is added on (Spiriva® Respimat® Product Monograph, 2017). If bronchodilation is 
conserved between these two populations, then the worsening trend with tiotropium and 
allergen-induced responses could occur in severe allergic asthmatics. Effects seen in clinical 
trials on mild allergic asthmatics are often extrapolated to the severe allergic asthma population. 
Tiotropium is currently indicated in severe asthma as an add on therapy in addition to 
ICS/LABA therapy in cases of poor control (Spiriva® Respimat® Product Monograph, 2017). 
Based on the present findings, we suggest further investigation into the regular use effect of 
tiotropium and the effect of tiotropium on allergen-induced late asthmatic responses and late 
sequelae to further elucidate the safety and efficacy of LAMA in allergic asthma. 
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5.0 GENERAL DISCUSSION 
This work has demonstrated the regular use effect of inhaled muscarinic antagonists on 
methacholine responsiveness (SAMA investigation) and allergen responsiveness (LAMA 
investigation). The results of these clinical trials contradict each other regarding safety of regular 
use of muscarinic antagonists. Bronchoprotection provided by single dose (40µg) ipratropium 
against methacholine-induced bronchoconstriction was maintained following 1-week of regular 
ipratropium (40µg thrice daily). This suggests that tolerance does not occur following regular 
stimulation of airway muscarinic receptors. In contrast, tolerance rapidly occurs to the 
bronchoprotective effect of b2-agonists after regular use (Bhagat et al., 1995; Bhagat et al., 1996; 
Boulet et al., 1998; Cheung et al., 1992; Drotar et al., 1998; O'Connor et al., 1992; Stewart et al., 
2012). Although originally observed with regular use of short-acting b2-agonists, tolerance also 
develops with regular use of long-acting b2-agonists and therefore, the development of tolerance 
appears to be a class effect.  
While it is unknown whether bronchoprotection against methacholine-induced constriction 
will be maintained following regular LAMA use, we previously (Cropper et al., 2020) assumed 
that this would be a class effect and that tolerance would not occur. The subsequent discovery of 
regular use tiotropium (5µg once daily for 1-week) and worsened early asthmatic responses to 
allergen suggests this may not be the case. Regular b2-agonists significantly enhance airway 
hyperresponsiveness to allergen during the EAR and LAR, an effect that coincides with the 
development of tolerance to bronchoprotection (Cockcroft et al., 2007; Cockcroft et al., 1993; 
Cockcroft et al., 1995). Therefore, our assumption that the absence of tolerance may occur with 
regular LAMA use could be wrong based on the observed allergen hyperresponsiveness. A 
previous study on regular SAMA use also reported no development of tolerance to the 
bronchoprotective effects of ipratropium after 2-weeks of regular use (60µg four times daily for 
3-weeks) (Newcomb et al., 1985). However, they found methacholine hyperresponsiveness 24-
hours after treatment withdrawal, suggesting that muscarinic receptors may have been 
upregulated or sensitized. Our study used a lower dose of ipratropium (40µg versus 60µg) for a 
shorter length (1-week versus 3-weeks) and therefore, the lower dose may have contributed to 
the lack of tolerance and hyperresponsiveness observed. It is of great interest whether regular use 
of tiotropium, with an effective half-life of 34-hours, will maintain bronchoprotection against 
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methacholine or whether tolerance will develop. We suggest future investigation into this topic, 
as it will help inform guidelines on usage of muscarinic antagonists as well as provide insight 
into the increased allergen responsiveness we observed with regular tiotropium.  
 A potential limitation of this work is the neutralizing effect of mean data that can 
minimize individual responses. Individual responses may become of greater importance in 
clinical research with the shift to personalized medicine. Previously reported variability in 
SAMA-treated individuals’ response to allergen, may be due to underlying factors that 
predispose some to better responses with cholinergic modulation (Cockcroft et al., 1978; Orehek 
et al., 1975; Yu et al., 1972). The present clinical trials used a relatively small populations, 
making the identification of sub-groups with alternative responses difficult.  
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Figure 5.1 Individual allergen and methacholine PD20 data for participants involved in both 







Four participants were involved in both present clinical trials and therefore their individual 
results under the two conditions are of interest (Fig. 5.1). Participants in panels A and C serve as 
representative examples for the trends observed in the mean data for both studies. Under regular 
use of ipratropium, these two participants did not develop tolerance to bronchoprotection with 
ipratropium or hyperresponsiveness to methacholine. With regular use of tiotropium, these two 
participants demonstrated slightly increased allergen responsiveness. Panel C represents a 
participant who had unique results in both studies. Following regular use of ipratropium, this 
participant exhibited stronger bronchoprotection against methacholine, evidenced by a greater 
MCh PD20 after 1-week of ipratropium (MCh PD20 = 753.6µg) in comparison to a single dose of 
ipratropium (MCh PD20 = 146.2µg). This participant demonstrated a strong placebo response, 
evidenced by a clinically significant dose shift (DS) in MCh PD20 after a single dose of 
ipratropium (DS = 2.4 doubling doses) and placebo treatments (DS = 2.2 doubling doses). 
Following regular tiotropium use, this participant required a greater dose of allergen (EAR PD20 
= 125.7 allergen units) to induce the same fall in FEV1 as with placebo treatment (EAR PD20 = 
96.2 allergen units). This was one of only three participants with reduced airway 
hyperresponsiveness to allergen after tiotropium treatment. Given the strong bronchoprotection 
placebo response seen under the ipratropium study, it is difficult to ascertain whether tiotropium 
had an isolated beneficial effect in this participant or if other factors are influencing this 
response. The mean data can be skewed by individual responses such as those displayed by the 
participant in panel B. Panel D represents a participant with a unique response to ipratropium and 
the reported response (increased allergen responsiveness) with tiotropium. After 1-week of 
ipratropium, this participant experienced less bronchoprotection (DS = 2.9) compared to after a 
single dose (DS = 4.0) and therefore tolerance may have occurred within this individual. Slight 
hyperresponsiveness to methacholine also occurred 24-hours after ipratropium withdrawal. 
Following 1-week of tiotropium treatment, this individual experienced increased allergen 
responsiveness, similar to the mean data. These participants demonstrate the potential for unique 
individual responses that may be due to important pathophysiological mechanisms, unexplained 
by mean data. With the shift towards personalized medicine, it may become important to 
incorporate case study and large sample size asthmatic clinical trials to identify sub-groups with 
differential responses.  
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Phenotyping and endotyping of asthma may improve treatment choice by identifying 
pathophysiological mechanisms underlying the disease. For example, sputum differential cell 
analyses identifying underlying eosinophilic airway inflammation in severe asthmatics indicates 
the use of an anti-IL-5 monoclonal antibody may be effective. Accumulating data, including the 
present data, suggest differing significance of cholinergic signalling among mild asthmatics. We 
suggest further investigation into the various factors contributing to differential responses to 
asthma therapies, including muscarinic antagonists. Furthermore, identification of specific 
features and biomarkers associated with asthma endotypes could improve diagnosis and 
management of asthma. 
This work provides a basis for further investigation into asthma management with inhaled 
muscarinic antagonists and their regular use effects. We suggest future clinical evaluation of the 
regular use effect of inhaled tiotropium on methacholine responsiveness and a single dose of 
tiotropium on allergen responsiveness to expand on the present findings. A major limitation of 
this work is the inability to determine mechanisms underlying the observed clinical effects. 
Further human tissue investigations with regular muscarinic antagonists may provide insight into 
underlying cellular events contributing to our findings.  
In summary, the muscarinic antagonists, ipratropium bromide (short-acting) and tiotropium 
bromide monohydrate (long-acting) were found to have opposed regular use effects on the 
bronchoconstricting stimuli, methacholine, and allergen, respectively. It is unclear whether this 
observed difference is due to the duration of action (short versus long-acting) or the body’s 
response to the stimulus (methacholine versus allergen). Non-neuronal cholinergic signalling 
remains an interesting and somewhat enigmatic player in immune responses that should continue 
to be studied in the human model. Future investigations may help guide clinical use of 
muscarinic antagonists as asthma management therapies.   
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